# 

**PIN Statistical analysis final report**

****  
**PIN: A randomised phase II trial of Olaparib maintenance versus placebo monotherapy in patients with chemosensitive advanced non-small cell lung cancer**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Name | Title | Signature | Date |
| Written by: | Catharine Porter | Dr |  |  |
| Validated and reviewed by: |  |  |  |  |
| Approved by: |  |  |  |  |

**Version history**

|  |  |  |
| --- | --- | --- |
| Version | Version date | Changes |
| 1.0 |  |  |
|  |  |  |
|  |  |  |

# Introduction

This document details the analysis for the main paper(s) reporting results from the PIN trial/study. Subsequent analyses of a more exploratory nature will not be bound by this strategy, though they are expected to follow the broad principles within this report.

The analysis strategy will be available on request when the principal papers are submitted for publication in a journal. Suggestions for subsequent analyses by journal editors or referees, will be considered carefully, and carried out as far as possible in line with the principles of this analysis strategy; if reported, the source of the suggestion will be acknowledged.

This report is based on the statistical analysis plan “Statistical Analysis Plan for

PIN : Parp Inhibitor in advanced NSCLC: A randomised phase II trial of Olaparib maintenance versus placebo monotherapy in patients with chemosensitive advanced non-small cell lung cancer” Version 2 dated 04/02/2019.

Any deviations from the statistical analysis plan will be described and justified in this report.

***Report written by:***

Catharine Porter

***Chief Investigators:***

Dean Fennell

***Trial/Study Manager:***

Georgina Gardner

# Validation

Validation of primary results presented in this report were conducted by Angela Casbard

All results/major endpoints/primary endpoint were validated by independent programming using STATA16. Results from output were checked for transcription errors. Further details of validation including validation programs are saved in: [S:\Centre for Trials Research\Research\Cancer\WCTU\Trials\WCTU Trials\PIN\15 Analysis\20190222 Final analysis\Final analysis documentation\QC checks](file:///\\scifs01.cf.ac.uk\s01\d01\Centre%20for%20Trials%20Research\Research\Cancer\WCTU\Trials\WCTU%20Trials\PIN\15%20Analysis\20190222%20Final%20analysis\Final%20analysis%20documentation\QC%20checks).

**Software employed**

The analysis was carried out using STATA 16 SE (StataCorp, 4905 Lakeway Drive, College Station, Texas 77845 USA)

# Results

# TRIAL/STUDY SAMPLE AND PARTICIPANT THROUGHPUT

SCREENING / ELIGIBILITY/ RECRUITMENT- See Figure 1

# RECRUITMENT-See Figure 1

# WITHDRAWAL/FOLLOW UP- See Figure 1

# BASELINE CHARACTERISTICS OF PARTICIPANT

See Table 1 and Table 2

# Analysis

# PRIMARY OUTCOME

# Primary analysis -See Figure 2 and Table13

# Sub group analyses-NA

# Sensitivity analyses-NA

# Missing data-NA

# Secondary analysis-See Figure 2 and Table13

# SECONDARY OUTCOMES-See Figure 3 and Tables 3, 6, 8, 9, 10, 12, 13

# Sub group analyses

# Sensitivity analyses

# Missing data

# ADDITIONAL ANALYSES-See Tables 4, 5, 7 and 14

# HARMS/SAFETY ANALYSES-See Tables 8, 9, 10, 15 and 16

# DEVIATIONS FROM STATISTICAL ANALYSIS PLAN

Sub-set analysis of overall survival in patients with squamous cell carcinoma and non-squamous cell carcinoma added (see Figures 3d and 3e).

Excluded (n=678)

Not eligible (n=678)

Assessed for eligibility for pre-induction chemotherapy registration (n=940)

Did not complete induction chemotherapy (n=38)

* Died (n=17)
* Withdrew (n=5)
* Toxicity (n=5)
* Chemo stopped early (n=4)
* Too ill (n=2)
* Found to be ineligible (n=2)
* Unknown (n=3)

Optional pre-induction chemotherapy registration (n=263)

Registered post-induction chemotherapy (n=39)

Excluded (n=194)

Not eligible (n=139)

* Not in CR/PR or NOT with other evidence of tumour shrinkage/Mixed stable (n=132)
* No CT scan or too ill or died before CT scan (n=7)

Eligible (n=55)

* Withdrew (n=7)
* CT scan done but not in timeframe for randomisation (n=4)
* No measurable disease/target lesions (n=2)
* Participant choice (n=1)
* Died (n=4)
* Unknown (n=44)

Assessed for eligibility for randomisation (n=264)

Randomised (n=70)

Allocated to Placebo (n=38)

Allocated to Olaparib (n=32)

Did not start study treatment (n=1)

Found to be ineligible (n=1)

Did not start study treatment (n=0)

Started study treatment and included in safety analysis (n=38)

Started study treatment and included in safety analysis (n=31)

Protocol deviation (n=0)

Protocol deviation (n=0)

Withdrew completely (n=8)

* Disease progression (n=6)
* Participant choice (n=1)
* Non-compliance (n=1)

Withdrew from trial treatment and still alive (n=6)

* Disease progression (n-6)

Died and not withdrawn (n=24)

* Disease progression (n=19)
* Central chest pain (n=1)
* Missing (n=4)

Lost to follow up prior to PFS event (n=0)

Withdrew completely before end of regimen (n=4)

* Disease progression (n=3)
* Participant choice (n=1)

Withdrew from trial treatment and still alive (n=8)

* Disease progression (n-8)

Died and not withdrawn (n=18)

* Disease progression (n=15)
* Missing (n=3)

Lost to follow up prior to PFS event (n=0)

Per protocol analysis:

Included (n=38)

Excluded (n=0)

Per protocol analysis:

Included (n=31)

Excluded (n=1)

Intention to treat analysis:

Included (n=38)

* Completed regimen (n=0)
* Did not complete regimen (n=38)
* Did not start treatment (n=0)

Excluded (n=0)

Intention to treat analysis:

Included (n=32)

* Completed regimen (n=1)
* Did not complete regimen (n=30)
* Did not start treatment (n=1)

Excluded (n=0)

Intention to treat analysis:

Included (n=32)

Excluded (n=0)

Figure 1: CONSORT flow diagram

Progression-free survival



Figure 2a: Kaplan-Meier of Progression-free survival (Intention-to treat population)

ITT unadjusted analysis:

HR 0.83 (80% CI 0.6-1.15; one-sided p-value 0.23)

There is no evidence that the proportional hazards assumption has been violated. Test of proportionality of hazards p-value=0.4



Figure 2b: Plot of Schoenfeld residuals to test PH (ITT population unadjusted)

Per protocol analysis



Figure 2c: Kaplan-Meier of progression-free survival (Per protocol population)

Per protocol unadjusted analysis:

HR 0.83 (80%CI 0.6-1.15; one-sided p-value 0.23)

There is no evidence that the proportional hazards assumption has been violated, Test of proportionality of hazards p-value=0.4



Figure 2d: Schoenfeld plot of residuals to test PH (PP population)

ITT Cox-adjusted model (adjusted for stratification factors-smoking history and histology):

HR 0.73 (80% CI 0.52-1.02; one-sided p-value 0.11)

There is no evidence that the proportional hazards assumption has been violated. Test of proportionality of hazards p-value=0.7



Figure 2e: Schoenfeld plot of residuals to test PH (Cox-model adjusted for stratification factors ITT population)

ITT Cox-adjusted model (adjusted for stratification factors (smoking history and histology) and unbalanced baseline characteristics (T-stage and N-stage)):

HR 0.79 (80% CI 0.54-1.17; p-value 0.45)

There is no evidence that the proportional hazards assumption has been violated. Test of proportionality of hazards p-value=0.5



Figure 2f: Schoenfeld plot of residuals to test PH (Cox-model adjusted for stratification factors and unbalanced baseline characteristics ITT population)

Overall survival



Figure 3a: Kaplan Meier of overall survival (ITT population)

HR 0.68 (95% CI 0.37-1.26; two-sided p-value 0.22).

There is no evidence that the proportional hazards assumption has been violated. Test of proportionality of hazards p-value=0.18



Follow-up



Figure 3c: Reverse Kaplan-Meier showing follow up of ITT population patients (still alive and not progressed).

Note that there were just 3 participants alive and not progressed at complete withdrawal and 1 patient that did not start treatment in the ITT population.

Overall survival in squamous cell carcinoma patients



Figure 3d: Overall survival in squamous cell carcinoma participants, by trial arm

HR 0.47 (95%CI 0.18-1.26) two-sided p-value 0.13

There is no evidence that the proportional hazards assumption has been violated. Test of proportionality of hazards p-value=0.1.

Median overall survival (months):

Placebo 7.3 (95%CI 4.5-11.4)

Olaparib 13.9 (9.0-.)

Overall survival in non-squamous cell carcinoma patients



Figure 3e: Overall survival in non-squamous cell carcinoma participants, by trial arm

HR 0.78 (95%CI 0.33-1.86) two-sided p-value 0.58

There is no evidence that the proportional hazards assumption has been violated. Test of proportionality of hazards p-value=0.47

Median overall survival (months):

Placebo 10.3 (95%CI 6.1-19.0)

Olaparib 12.3 (95%CI 4.3-15.8)

Figure 4: Not done as no difference found between the arms

**Tables**

Table 1: Medical History

| **Table 1: Medical History** | **Olaparib** | **Placebo** |
| --- | --- | --- |
| N=32 | N=38 |
| **Non-small cell lung cancer type - N (%)** |  |  |
| Adenocarcinoma | 19 (59.4) | 18 (47.4) |
| Squamous | 13 (40.6) | 18 (47.4) |
| Other | 0 (0.0) | 2 (5.3) |
| Large cell nos | 0 (0.0) | 1 (2.6) |
| Mixed adenocarcinoma/Squamous | 0 (0.0) | 1 (2.6) |
| **T stage - N (%)** |  |  |
| T1 | 3 (9.4) | 2 (5.3) |
| T2 | 6 (18.8) | 3 (7.9) |
| T3 | 10 (31.3) | 6 (15.8) |
| T4 | 12 (37.5) | 23 (60.5) |
| TX | 0 (0.0) | 3 (7.9) |
| Missing | 1 (3.1) | 1 (2.6) |
| **N stage - N (%)** |  |  |
| N0 | 6 (18.8) | 2 (5.3) |
| N1 | 1 (3.1) | 3 (7.9) |
| N2 | 9 (28.1) | 16 (42.1) |
| N3 | 13 (40.6) | 15 (39.5) |
| NX | 2 (6.3) | 1 (2.6) |
| Missing | 1 (3.1) | 1 (2.6) |
| **M stage - N (%)** |  |  |
| M0 | 10 (31.3) | 10 (26.3) |
| M1a | 10 (31.3) | 15 (39.5) |
| M1b | 11 (34.4) | 13 (34.2) |
| Missing | 1 (3.1) | 0 (0.0) |
| **Stage of NSCLC - N (%)** |  |  |
| IIIB | 10 (31.3) | 13 (34.2) |
| IV | 22 (68.8) | 25 (65.8) |
| **Sites affected - N (%)** |  |  |
| Oesophagus | 1 (3.1) | 1 (2.6) |
| Chest wall | 1 (3.1) | 2 (5.3) |
| Trachea | 2 (6.3) | 3 (7.9) |
| Pleura | 8 (25.0) | 3 (7.9) |
| Heart pericardium | 1 (3.1) | 2 (5.3) |
| Liver metastases | 5 (15.6) | 3 (7.9) |
| Lung metastases | 11 (34.4) | 15 (39.5) |
| Bones metastases | 6 (18.8) | 5 (13.2) |
| Brain metastases | 1 (3.1) | 1 (2.6) |
| Adrenal gland | 3 (9.4) | 2 (5.3) |
| Other |  |  |
| *Primary mass* | 1 (3.1) |  |
| *Lung* |  | 1 (2.6) |
| *Right upper lobe* | 2 (6.3) | 3 (7.9) |
| *Mediastinum* | 3 (9.4) | 3 (7.9) |
| *Left lower lobe of bronchus compressing including the oesophagus* |  | 1 (2.6) |
| *Pericardial effusion* |  | 1 (2.6) |
| *Right main bronchus* |  | 1 (2.6) |
| *Pulmonary artery* |  | 1 (2.6) |
| *Regional nodes* | 1 (3.1) |  |
| *Retroperitoneal* |  | 1 (2.6) |
| *Ipsilateral hilar, Mediastinal and supraclavicular nodes* | 1 (3.1) |  |
| *Right hilar* | 2 | 1 (2.6) |
| *Left hilar region subcarninal region lymph node by lower thoracic aorta* |  | 1 (2.6) |
| *Hilar nodes* |  | 1 (2.6) |
| *Subcarinal lymph nodes* | 1 (3.1) | 1 (2.6) |
| *Sub-aortic lymph node* |  | 1 (2.6) |
| *Side neck nodes* |  | 1 (2.6) |
| *Right neck lymph nodes* |  | 1 (2.6) |
| *Pre-tracheal lymph node* | 1 (3.1) |  |
| *Para-aortic lymph node* |  | 1 (2.6) |
| *Lymph nodes (unspecified)* | 1 (3.1) | 2 (5.3) |
| *Distant nodes* | 1 (3.1) |  |
| *Rib* | 1 (3.1) |  |
| *Spleen* |  | 1 (2.6) |
| *Right upper pole renal lesion* | 1 (3.1) |  |
| **Type of induction chemotherapy treatment - N (%)** |  |  |
| Gemcitabine | 10 (31.3) | 14 (36.8) |
| Cisplatin | 6 (18.8) | 7 (18.4) |
| Carboplatin | 18 (56.3) | 27 (71.1) |
| Pemetrexed | 17 (53.1) | 17 (44.7) |
| Paclitaxel | 1 (3.1) | 0 (0.0) |
| Vinorelbine | 4 (12.5) | 4 (10.5) |
| Other | 5 (15.6) | 5 (13.2) |
| Docetaxel | 0 (0.0) | 1 (2.6) |
| Not available | 5 (15.6) | 4 (10.5) |
| **Number of cycles of induction chemotherapy - n, median(IQR)** | 32, 4 (4-4) | 38, 4 (4-4) |
| **Response to induction chemotherapy - N (%)** |  |  |
| Complete response | 2 (6.3) | 1 (2.6) |
| Partial response | 28 (87.5) | 34 (89.5) |
| Other evidence of tumour shrinkage/Mixed stable | 2 (6.3) | 3 (7.9) |

Table 2: Pre-randomisation baseline characteristics

| **Table 2: Pre-randomisation baseline characteristics** | **Olaparib** | **Placebo** |
| --- | --- | --- |
| N=32 | N=38 |
| **Sex - N (%)** |  |  |
| Male | 16 (50.0) | 24 (63.2) |
| Female | 16 (50.0) | 14 (36.8) |
| **Age - n, median(IQR)** | 31, 64.7 (60.5-71.5) | 38, 63.3 (58.6-69.9) |
| **Smoking history - N (%)** |  |  |
| Never smoked | 3 (9.4) | 3 (7.9) |
| Ever smoked | 29 (90.6) | 35 (92.1) |
| **Systolic BP - n, median(IQR)** | 32, 133.0 (123.5-150.0) | 38, 132.0 (124.0-146.0) |
| **Diastolic BP - n, median(IQR)** | 32, 73.5 (69.5-86.5) | 38, 76.5 (73.0-87.0) |
| **Oxygen saturation - n, median(IQR)** | 30, 97.5 (97.0-98.0) | 38, 97.0 (96.0-98.0) |
| **Pulse - n, median(IQR)** | 32, 80.0 (74.0-88.5) | 38, 86.0 (77.0-95.0) |
| **Weight - n, median(IQR)** | 32, 75.7 (63.3-83.6) | 38, 74.9 (62.3-93.8) |
| **ECOG status - N (%)** |  |  |
| 0 | 9 (28.1) | 13 (34.2) |
| 1 | 23 (71.9) | 25 (65.8) |
| **ECG Resting QTc - n, median(IQR)** | 32, 425.5 (413.0-439.0) | 37, 431.0 (417.0-445.0) |
| URINALYSIS |  |  |
| **pH Normal - N (%)** |  |  |
| Yes | 28 (87.5) | 32 (84.2) |
| No | 3 (9.4) | 4 (10.5) |
| Missing | 1 (3.1) | 2 (5.3) |
| **pH clinically significant - N (%)** |  |  |
| Yes | 1 (3.1) | 0 (0.0) |
| No | 30 (93.8) | 36 (94.7) |
| Missing | 1 (3.1) | 2 (5.3) |
| **Glucose Normal - N (%)** |  |  |
| Yes | 31 (96.9) | 33 (86.8) |
| No | 0 (0.0) | 3 (7.9) |
| Missing | 1 (3.1) | 2 (5.3) |
| **Glucose clinically significant - N (%)** |  |  |
| Yes | 1 (3.1) | 2 (5.3) |
| No | 30 (93.8) | 34 (89.5) |
| Missing | 1 (3.1) | 2 (5.3) |
| **Blood Normal - N (%)** |  |  |
| Yes | 26 (81.3) | 31 (81.6) |
| No | 5 (15.6) | 5 (13.2) |
| Missing | 1 (3.1) | 2 (5.3) |
| **Blood clinically significant - N (%)** |  |  |
| Yes | 2 (6.3) | 3 (7.9) |
| No | 29 (90.6) | 33 (86.8) |
| Missing | 1 (3.1) | 2 (5.3) |
| **Protein Normal - N (%)** |  |  |
| Yes | 25 (78.1) | 31 (81.6) |
| No | 6 (18.8) | 5 (13.2) |
| Missing | 1 (3.1) | 2 (5.3) |
| **Protein clinically significant - N (%)** |  |  |
| Yes | 0 (0.0) | 3 (7.9) |
| No | 31 (96.9) | 33 (86.8) |
| Missing | 1 (3.1) | 2 (5.3) |
| **Leucocytes Normal - N (%)** |  |  |
| Yes | 29 (90.6) | 35 (92.1) |
| No | 1 (3.1) | 1 (2.6) |
| Missing | 2 (6.3) | 2 (5.3) |
| **Leucocytes clinically significant - N (%)** |  |  |
| Yes | 1 (3.1) | 1 (2.6) |
| No | 29 (90.6) | 35 (92.1) |
| Missing | 2 (6.3) | 2 (5.3) |
| Blood results - n, median (IQR) |  |  |
| Serum creatinine - umol/L | 32, 73.5 (60.0-82.0) | 38, 76.5 (60.0-84.0) |
| Urea - mmol/L | 30, 5.3 (3.8-5.9) | 38, 4.6 (3.2-5.9) |
| Corrected calcium - mmol/L | 32, 2.4 (2.4-2.5) | 38, 2.4 (2.3-2.4) |
| Albumin - g/L | 32, 41.0 (39.5-43.5) | 38, 42.0 (38.0-44.0) |
| Neutrophils - 10^9/L | 32, 3.4 (2.3-4.8) | 38, 4.0 (3.1-5.8) |
| WBC - 10^9/L | 32, 5.4 (4.3-7.3) | 38, 6.7 (5.8-9.0) |
| ALT - IU/L | 30, 18.0 (14.0-28.0) | 37, 23.0 (13.0-30.0) |
| ALP - IU/L | 30, 86.0 (78.0-107.0) | 36, 93.5 (72.5-114.0) |
| Serum bilirubin - umol/L | 32, 6.0 (4.5-7.5) | 37, 6.0 (5.0-8.0) |
| Potassium - mmol/L | 32, 4.4 (4.2-4.6) | 37, 4.2 (4.0-4.7) |
| Sodium - mmol/L | 31, 140.0 (137.0-142.0) | 38, 138.5 (137.0-141.0) |
| Platelets - 10^9/L | 32, 319.0 (249.0-407.0) | 38, 322.5 (228.0-417.0) |
| Haemoglobin - 10^9/L | 32, 107.5 (103.0-119.5) | 38, 115.5 (105.0-124.0) |
| RBC - 10^12/L | 32, 3.5 (3.3-3.9) | 38, 3.6 (3.3-3.9) |
| AST - IU/L | 24, 19.5 (18.0-24.5) | 26, 22.0 (17.0-27.0) |
| **Site of target tumour - N (%)** |  |  |
| Primary | 22 (68.8) | 24 (63.2) |
| Lymph node | 4 (12.5) | 7 (18.4) |
| Liver | 1 (3.1) | 1 (2.6) |
| Adrenal glands | 2 (6.3) | 2 (5.3) |
| Other (specify) | 2 (6.3) | 4 (10.5) |
| *Left upper lobe mass* | 1 (3.1) | 1 (2.6) |
| *Right apical lower lobe* | 1 (3.1) |  |
| *Central left lung mass* |  | 1 (2.6) |
| *Apical left lower lobe metastases* |  | 1 (2.6) |
| *Left anterior lung mass* | 1 (3.1) |  |
| *Left lower lobe basal met* |  | 1 (2.6) |
| *Right basal lung mass* | 1 (3.1) |  |
| *Left lower lobe tumour mass* |  | 1 (2.6) |
| *Inferior lingula met* |  | 1 (2.6) |
| *Aortopulmonary soft tissue mass* |  | 1 (2.6) |
| *Anterior mediastinal mass* | 1 (3.1) |  |
| *Low right paratrachael / precarninal node* |  | 1 (2.6) |
| *Subcarinal node* |  | 1 (2.6) |
| *Paracardiac chest wall mass* |  | 1 (2.6) |
| *Splenic lesion* |  | 1 (2.6) |
| **Longest Diameter of tumours - n, median (IQR)** |  |  |
| Primary | 22, 29.5 (15.0-40.0) | 24, 39.5 (24.0-55.5) |
| Lymph node | 4, 16.5 (13.5-19.0) | 7, 16.0 (10.0-19.0) |
| Liver | 1, 14.0 (14.0-14.0) | 1, 26.0 (26.0-26.0) |
| Adrenal glands | 2, 47.5 (36.0-59.0) | 2, 15.5 (11.0-20.0) |
| Other | 2, 34.5 (30.0-39.0) | 4, 35.0 (24.5-46.0) |
| **Sum of Longest Diameters - n, median (IQR)** | 30, 53.5 (30.0-69.0) | 36, 44.5 (33.0-62.5) |
| **Pre-induction chemotherapy blood sample was taken for translational purposes - N (%)** |  |  |
| Yes | 14 (100.0) | 18 (90.0) |
| No | 0 (0.0) | 2 (10.0) |
| **Post-induction chemotherapy blood sample was taken for translational purposes - N (%)** |  |  |
| Yes | 31 (96.9) | 32 (84.2) |
| No | 0 (0.0) | 5 (13.2) |
| Missing | 1 (3.1) | 1 (2.6) |
| **The patient's archival tissue block has been requested for translational purposes - N (%)** |  |  |
| Yes | 23 (71.9) | 26 (68.4) |
| Unknown | 9 (28.1) | 12 (31.6) |

Table 3: Treatment Details

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 3 : Treatment compliance** | **Cycle 1** | | **Cycle 2** | | **Cycle 3** | | **Cycle 4** | |
| **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** |
| **N=31** | **N=38** | **N=29** | **N=35** | **N=20** | **N=25** | **N=17** | **N=23** |
| **Olaparib/placebo given to the patient - N (%)** | 31 (100.0) | 38 (100.0) | 29 (100.0) | 35 (100.0) | 20 (100.0) | 25 (100.0) | 17 (100.0) | 23 (100.0) |
| **Dose of Olaparib/placebo administered (mg) - n, median (IQR)** | 31, 12600.0 (12600.0-12600.0) | 38, 12600.0 (12600.0-12600.0) | 29, 12600.0 (12600.0-12600.0) | 35, 12600.0 (12600.0-12600.0) | 20, 12600.0 (12150.0-12600.0) | 25, 12600.0 (12600.0-12600.0) | 17, 12600.0 (12600.0-12600.0) | 23, 12600.0 (10500.0-12600.0) |
| **Dose reduction of Olaparib/placebo - N (%)** | 0 (0.0) | 0 (0.0) | 3 (10.3) | 2 (5.7) | 2 (10.0) | 1 (4.0) | 1 (5.9) | 3 (13.0) |
| **Dose delay of Olaparib/placebo - N (%)** | 3 (9.7) | 4 (10.5) | 4 (13.8) | 6 (17.1) | 3 (15.0) | 4 (16.0) | 4 (23.5) | 4 (17.4) |
| **Withdrawal from trial treatment - N (%)** | 2 (6.5) | 3 (7.9) | 9 (31.0) | 11 (31.4) | 3 (15.0) | 2 (8.0) | 4 (23.5) | 8 (34.8) |
|  |  |  |  |  |  |  |  |  |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  | **Cycle 5** | | **Cycle 6** | | **Cycle 7** | | **Cycle 8** | |
| **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** |
| **N=13** | **N=15** | **N=11** | **N=13** | **N=6** | **N=7** | **N=6** | **N=6** |
| **Olaparib/placebo given to the patient - N (%)** | 13 (100.0) | 15 (100.0) | 11 (100.0) | 13 (100.0) | 6 (100.0) | 7 (100.0) | 6 (100.0) | 6 (100.0) |
| **Dose of Olaparib/placebo administered (mg) - n, median (IQR)** | 13, 12600.0 (12600.0-12600.0) | 15, 12600.0 (12300.0-12600.0) | 11, 12600.0 (12600.0-12600.0) | 13, 12600.0 (12600.0-12600.0) | 6, 12450.0 (12300.0-12600.0) | 7, 12600.0 (12600.0-12600.0) | 6, 12600.0 (4200.0-12600.0) | 6, 12600.0 (12300.0-12600.0) |
| **Dose reduction of Olaparib/placebo - N (%)** | 1 (7.7) | 2 (13.3) | 0 (0.0) | 2 (15.4) | 0 (0.0) | 1 (14.3) | 0 (0.0) | 1 (16.7) |
| **Dose delay of Olaparib/placebo - N (%)** | 2 (15.4) | 3 (20.0) | 0 (0.0) | 4 (30.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (16.7) |
| **Withdrawal from trial treatment - N (%)** | 2 (15.4) | 2 (13.3) | 5 (45.5) | 6 (46.2) | 0 (0.0) | 1 (14.3) | 3 (50.0) | 5 (83.3) |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  | **Cycle 9** | | **Cycle 10** | | **Cycle 11** | | **Cycle 12** | |
| **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** |
| **N=3** | **N=1** | **N=2** | **N=1** | **N=2** | **N=0** | **N=2** | **N=0** |
| **Olaparib/placebo given to the patient - N (%)** | 3 (100.0) | 1 (100.0) | 2 (100.0) | 1 (100.0) | 2 (100.0) | 0 (.) | 2 (100.0) | 0 (.) |
| **Dose of Olaparib/placebo administered (mg) - n, median (IQR)** | 3, 12600.0 (12450.0-12600.0) | 1, 12600.0 (12600.0-12600.0) | 2, 12600.0 (12600.0-12600.0) | 1, 12600.0 (12600.0-12600.0) | 2, 12600.0 (12600.0-12600.0) | - | 2, 12600.0 (12600.0-12600.0) | - |
| **Dose reduction of Olaparib/placebo - N (%)** | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | - | 0 (0.0) | - |
| **Dose delay of Olaparib/placebo - N (%)** | 0 (0.0) | 1 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | - | 0 (0.0) | - |
| **Withdrawal from trial treatment - N (%)** | 1 (33.3) | 0 (0.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | - | 1 (50.0) | - |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  | **Cycle 13** | | **Cycle 14** | | **Cycle 15** | | **Cycle 16** | |
| **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** |
| **N=1** | **N=0** | **N=1** | **N=0** | **N=1** | **N=0** | **N=1** | **N=0** |
| **Dose of Olaparib/placebo administered (mg) - n, median (IQR)** | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) |
| **Dose reduction of Olaparib/placebo - N (%)** | 1, 12600.0 (12600.0-12600.0) | - | 1, 12600.0 (12600.0-12600.0) | - | 1, 12600.0 (12600.0-12600.0) | - | 1, 12600.0 (12600.0-12600.0) | - |
| **Dose delay of Olaparib/placebo - N (%)** | 0 (0.0) | - | 0 (0.0) | - | 0 (0.0) | - | 0 (0.0) | - |
| **Withdrawal from trial treatment - N (%)** | 1 (100.0) | - | 1 (100.0) | - | 0 (0.0) | - | 0 (0.0) | - |
|  | 0 (0.0) | - | 0 (0.0) | - | 0 (0.0) | - | 0 (0.0) | - |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  | **Cycle 17** | | **Cycle 18** | |  |  |  |  |
| **Olaparib** | **Placebo** | **Olaparib** | **Placebo** |  |  |  |  |
| **N=1** | **N=0** | **N=1** | **N=0** |  |  |  |  |
| **Olaparib/placebo given to the patient - N (%)** | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) |  |  |  |  |
| **Dose of Olaparib/placebo administered (mg) - n, median (IQR)** | 1, 12600.0 (12600.0-12600.0) | - | 1, 12600.0 (12600.0-12600.0) | - |  |  |  |  |
| **Dose reduction of Olaparib/placebo - N (%)** | 0 (0.0) | - | 0 (0.0) | - |  |  |  |  |
| **Dose delay of Olaparib/placebo - N (%)** | 0 (0.0) | - | 0 (0.0) | - |  |  |  |  |
| **Withdrawal from trial treatment - N (%)** | 0 (0.0) | - | 0 (0.0) | - |  |  |  |  |

Relative dose intensity (%) (median;IQR) in the Olaparib arm is 86.4 (64.3-95.7) and in the Placebo arm is 93.3 (80.2-97.6). Relative dose intensity is calculated as defined in the Statistical Analysis Plan as:

* + PD=Planned protocol dose per 21 day Cycle=300x2x21=12600mg
  + AD= Actual dose per 21 day cycle = (Dose prescribedx2x21) -N tablets missed x150(mg)-N tablets missed x100(mg) – (N days delayed/withdrawn x prescribed dose x 2)

Relative dose intensity RDI = sum of AD for each cycle received /(PDx[days until end of trial / 21]).

Median duration of treatment (cycles) (IQR) in the Olaparib arm is 3.9 (2.3-6.3) and in the Placebo arm is 4.0 (2.0-6.0).

Table 4: Physical exam and ECOG status

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 4 : Physical examination and ECOG status** | **Cycle 1** | | **Cycle 2** | | **Cycle 3** | | **Cycle 4** | |
| **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** |
| **N=31** | **N=38** | **N=29** | **N=35** | **N=20** | **N=25** | **N=17** | **N=23** |
| **Systolic BP - n, median (IQR)** | 31, 139.0 (125.0-151.0) | 38, 132.5 (127.0-148.0) | 29, 131.0 (121.0-144.0) | 35, 139.0 (130.0-156.0) | 19, 129.0 (117.0-143.0) | 25, 137.0 (127.0-150.0) | 17, 121.0 (111.0-132.0) | 21, 141.0 (123.0-152.0) |
| **Diastolic BP - n, median (IQR)** | 31, 75.0 (71.0-87.0) | 38, 79.5 (75.0-87.0) | 29, 73.0 (66.0-77.0) | 35, 80.0 (76.0-91.0) | 18, 71.0 (66.0-74.0) | 25, 82.0 (72.0-87.0) | 17, 75.0 (66.0-77.0) | 21, 88.0 (70.0-95.0) |
| **Oxygen saturation - n, median (IQR)** | 29, 98.0 (97.0-99.0) | 37, 97.0 (96.0-98.0) | 28, 97.5 (97.0-98.0) | 31, 97.0 (96.0-98.0) | 18, 97.0 (96.0-98.0) | 24, 97.0 (96.0-98.0) | 16, 97.0 (97.0-98.0) | 20, 97.0 (96.0-98.0) |
| **Pulse - n, median (IQR)** | 31, 82.0 (76.0-88.0) | 38, 88.0 (79.0-95.0) | 29, 81.0 (75.0-89.0) | 35, 85.0 (78.0-94.0) | 19, 77.0 (69.0-86.0) | 25, 81.0 (76.0-86.0) | 17, 81.0 (75.0-83.0) | 21, 83.0 (76.0-93.0) |
| **Weight - n, median (IQR)** | 31, 78.6 (64.2-83.6) | 37, 75.4 (62.0-93.7) | 29, 78.6 (63.8-83.8) | 34, 77.1 (66.0-95.7) | 19, 79.3 (62.0-84.5) | 24, 78.4 (66.5-95.4) | 16, 70.1 (60.1-88.7) | 22, 78.2 (67.0-102.0) |
| **ECOG status - n, median (IQR)** | 31, 1.0 (0.0-1.0) | 38, 1.0 (0.0-1.0) | 29, 1.0 (1.0-1.0) | 35, 1.0 (0.0-1.0) | 20, 1.0 (1.0-1.0) | 25, 1.0 (1.0-1.0) | 17, 1.0 (0.0-1.0) | 22, 1.0 (0.0-1.0) |
| **ECOG status - N (%)** |  |  |  |  |  |  |  |  |
| 0 | 8 (25.8) | 10 (26.3) | 6 (20.7) | 9 (25.7) | 4 (20.0) | 6 (24.0) | 5 (29.4) | 7 (30.4) |
| 1 | 23 (74.2) | 28 (73.7) | 23 (79.3) | 26 (74.3) | 16 (80.0) | 19 (76.0) | 12 (70.6) | 15 (65.2) |
| 2 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 3 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Missing | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (4.3) |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  | **Cycle 5** | | **Cycle 6** | | **Cycle 7** | | **Cycle 8** | |
| **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** |
| **N=13** | **N=15** | **N=11** | **N=13** | **N=6** | **N=7** | **N=6** | **N=6** |
| **Systolic BP - n, median (IQR)** | 13, 126.0 (117.0-144.0) | 15, 143.0 (130.0-156.0) | 10, 122.0 (114.0-136.0) | 13, 147.0 (135.0-157.0) | 6, 144.5 (130.0-155.0) | 7, 137.0 (114.0-172.0) | 5, 130.0 (130.0-134.0) | 6, 148.5 (135.0-161.0) |
| **Diastolic BP - n, median (IQR)** | 13, 73.0 (67.0-82.0) | 15, 82.0 (74.0-88.0) | 10, 72.0 (65.0-79.0) | 13, 80.0 (76.0-83.0) | 6, 82.0 (79.0-88.0) | 7, 78.0 (67.0-89.0) | 5, 73.0 (72.0-85.0) | 6, 82.5 (77.0-84.0) |
| **Oxygen saturation - n, median (IQR)** | 13, 98.0 (97.0-98.0) | 13, 96.0 (96.0-97.0) | 10, 98.0 (98.0-99.0) | 13, 97.0 (96.0-98.0) | 6, 97.0 (97.0-99.0) | 7, 98.0 (96.0-98.0) | 5, 96.0 (95.0-98.0) | 5, 98.0 (98.0-99.0) |
| **Pulse - n, median (IQR)** | 13, 79.0 (76.0-86.0) | 15, 90.0 (74.0-92.0) | 10, 75.0 (62.0-83.0) | 13, 78.0 (67.0-86.0) | 6, 75.5 (72.0-82.0) | 7, 79.0 (74.0-82.0) | 5, 80.0 (72.0-82.0) | 6, 75.5 (72.0-86.0) |
| **Weight - n, median (IQR)** | 13, 70.6 (61.3-83.9) | 14, 76.9 (66.4-93.1) | 11, 70.2 (60.6-82.5) | 13, 75.7 (68.4-93.0) | 6, 68.8 (58.4-82.1) | 6, 77.5 (67.4-96.3) | 6, 68.5 (58.4-81.9) | 6, 88.6 (75.3-101.4) |
| **ECOG status - n, median (IQR)** | 13, 1.0 (1.0-1.0) | 15, 1.0 (0.0-1.0) | 11, 1.0 (0.0-1.0) | 13, 1.0 (1.0-1.0) | 6, 1.0 (0.0-1.0) | 7, 1.0 (1.0-1.0) | 6, 0.5 (0.0-1.0) | 6, 0.5 (0.0-1.0) |
| **ECOG status - N (%)** |  |  |  |  |  |  |  |  |
| 0 | 2 (15.4) | 5 (33.3) | 3 (27.3) | 3 (23.1) | 2 (33.3) | 1 (14.3) | 3 (50.0) | 3 (50.0) |
| 1 | 11 (84.6) | 9 (60.0) | 8 (72.7) | 10 (76.9) | 4 (66.7) | 6 (85.7) | 3 (50.0) | 3 (50.0) |
| 2 | 0 (0.0) | 1 (6.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 3 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Missing | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  | **Cycle 9** | | **Cycle 10** | | **Cycle 11** | | **Cycle 12** | |
| **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** |
| **N=3** | **N=1** | **N=2** | **N=1** | **N=2** | **N=0** | **N=2** | **N=0** |
| **Systolic BP - n, median (IQR)** | 3, 138.0 (118.0-147.0) | 1, 150.0 (150.0-150.0) | 2, 128.0 (127.0-129.0) | 1, 147.0 (147.0-147.0) | 2, 140.5 (128.0-153.0) | - | 2, 150.0 (149.0-151.0) | - |
| **Diastolic BP - n, median (IQR)** | 3, 79.0 (52.0-83.0) | 1, 59.0 (59.0-59.0) | 2, 84.5 (83.0-86.0) | 1, 73.0 (73.0-73.0) | 2, 83.0 (75.0-91.0) | - | 2, 71.0 (59.0-83.0) | - |
| **Oxygen saturation - n, median (IQR)** | 3, 99.0 (97.0-100.0) | 1, 98.0 (98.0-98.0) | 2, 96.5 (96.0-97.0) | 1, 97.0 (97.0-97.0) | 2, 97.5 (97.0-98.0) | - | 2, 99.5 (99.0-100.0) | - |
| **Pulse - n, median (IQR)** | 3, 77.0 (60.0-82.0) | 1, 76.0 (76.0-76.0) | 2, 77.5 (75.0-80.0) | 1, 100.0 (100.0-100.0) | 2, 80.5 (79.0-82.0) | - | 2, 74.0 (70.0-78.0) | - |
| **Weight - n, median (IQR)** | 3, 71.6 (45.0-82.8) | 1, 66.8 (66.8-66.8) | 2, 77.3 (71.2-83.3) | 1, 66.6 (66.6-66.6) | 2, 76.0 (70.4-81.7) | - | 2, 77.0 (71.0-83.0) | - |
| **ECOG status - n, median (IQR)** | 3, 0.0 (0.0-1.0) | 1, 0.0 (0.0-0.0) | 2, 0.5 (0.0-1.0) | 1, 1.0 (1.0-1.0) | 2, 0.5 (0.0-1.0) | - | 2, 0.5 (0.0-1.0) | - |
| **ECOG status - N (%)** |  |  |  |  |  |  |  |  |
| 0 | 2 (66.7) | 1 (100.0) | 1 (50.0) | 0 (0.0) | 1 (50.0) | - | 1 (50.0) | - |
| 1 | 1 (33.3) | 0 (0.0) | 1 (50.0) | 1 (100.0) | 1 (50.0) | - | 1 (50.0) | - |
| 2 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | - | 0 (0.0) | - |
| 3 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | - | 0 (0.0) | - |
| 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | - | 0 (0.0) | - |
| Missing | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | - | 0 (0.0) | - |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  | **Cycle 13** | | **Cycle 14** | | **Cycle 15** | | **Cycle 16** | |
| **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** |
| **N=1** | **N=0** | **N=1** | **N=0** | **N=1** | **N=0** | **N=1** | **N=0** |
| **Systolic BP - n, median (IQR)** | 1, 151.0 (151.0-151.0) | - | 1, 125.0 (125.0-125.0) | - | 1, 134.0 (134.0-134.0) | - | 1, 102.0 (102.0-102.0) | - |
| **Diastolic BP - n, median (IQR)** | 1, 59.0 (59.0-59.0) | - | 1, 72.0 (72.0-72.0) | - | 1, 64.0 (64.0-64.0) | - | 1, 60.0 (60.0-60.0) | - |
| **Oxygen saturation - n, median (IQR)** | 1, 99.0 (99.0-99.0) | - | 1, 98.0 (98.0-98.0) | - | 1, 98.0 (98.0-98.0) | - | 1, 91.0 (91.0-91.0) | - |
| **Pulse - n, median (IQR)** | 1, 70.0 (70.0-70.0) | - | 1, 82.0 (82.0-82.0) | - | 1, 78.0 (78.0-78.0) | - | 1, 83.0 (83.0-83.0) | - |
| **Weight - n, median (IQR)** | 1, 71.0 (71.0-71.0) | - | 1, 68.6 (68.6-68.6) | - | 1, 69.2 (69.2-69.2) | - | 1, 68.9 (68.9-68.9) | - |
| **ECOG status - n, median (IQR)** | 1, 1.0 (1.0-1.0) | - | 1, 1.0 (1.0-1.0) | - | 1, 1.0 (1.0-1.0) | - | 1, 2.0 (2.0-2.0) | - |
| **ECOG status - N (%)** |  |  |  |  |  |  |  |  |
| 0 | 0 (0.0) | - | 0 (0.0) | - | 0 (0.0) | - | 0 (0.0) | - |
| 1 | 1 (100.0) | - | 1 (100.0) | - | 1 (100.0) | - | 0 (0.0) | - |
| 2 | 0 (0.0) | - | 0 (0.0) | - | 0 (0.0) | - | 1 (100.0) | - |
| 3 | 0 (0.0) | - | 0 (0.0) | - | 0 (0.0) | - | 0 (0.0) | - |
| 4 | 0 (0.0) | - | 0 (0.0) | - | 0 (0.0) | - | 0 (0.0) | - |
| Missing | 0 (0.0) | - | 0 (0.0) | - | 0 (0.0) | - | 0 (0.0) | - |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  | **Cycle 17** | | **Cycle 18** | | **30 days post treatment** | |  |  |
| **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** |  |  |
| **N=1** | **N=0** | **N=1** | **N=0** | **N=9** | **N=6** |  |  |
| **Systolic BP - n, median (IQR)** | 1, 123.0 (123.0-123.0) | - | 1, 129.0 (129.0-129.0) | - | 8, 138.0 (133.0-144.5) | 5, 121.0 (121.0-127.0) |  |  |
| **Diastolic BP - n, median (IQR)** | 1, 65.0 (65.0-65.0) | - | 1, 70.0 (70.0-70.0) | - | 8, 73.5 (67.0-86.5) | 5, 79.0 (73.0-79.0) |  |  |
| **Oxygen saturation - n, median (IQR)** | 1, 92.0 (92.0-92.0) | - | 1, 99.0 (99.0-99.0) | - | 6, 96.5 (95.0-97.0) | 5, 95.0 (95.0-97.0) |  |  |
| **Pulse - n, median (IQR)** | 1, 87.0 (87.0-87.0) | - | 1, 81.0 (81.0-81.0) | - | 8, 86.0 (82.0-92.5) | 5, 92.0 (89.0-99.0) |  |  |
| **Weight - n, median (IQR)** | 1, 67.9 (67.9-67.9) | - | 1, 68.0 (68.0-68.0) | - | 8, 80.5 (72.6-86.2) | 5, 72.8 (63.0-92.5) |  |  |
| **ECOG status - n, median (IQR)** | 1, 1.0 (1.0-1.0) | - | 1, 1.0 (1.0-1.0) | - | 7, 1.0 (1.0-1.0) | 6, 1.0 (1.0-1.0) |  |  |
| **ECOG status - N (%)** |  |  |  |  |  |  |  |  |
| 0 | 0 (0.0) | - | 0 (0.0) | - | 1 (11.1) | 1 (16.7) |  |  |
| 1 | 1 (100.0) | - | 1 (100.0) | - | 6 (66.7) | 4 (66.7) |  |  |
| 2 | 0 (0.0) | - | 0 (0.0) | - | 0 (0.0) | 1 (16.7) |  |  |
| 3 | 0 (0.0) | - | 0 (0.0) | - | 0 (0.0) | 0 (0.0) |  |  |
| 4 | 0 (0.0) | - | 0 (0.0) | - | 0 (0.0) | 0 (0.0) |  |  |
| Missing | 0 (0.0) | - | 0 (0.0) | - | 2 (22.2) | 0 (0.0) |  |  |

Table 5: Urinalysis, blood tests and serum biochemistry

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 5 : Urinalysis, blood tests and serum biochemistry** | **Cycle 1** | | **Cycle 2** | | **Cycle 3** | | **Cycle 4** | |
| **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** |
| **N=31** | **N=38** | **N=29** | **N=35** | **N=20** | **N=25** | **N=17** | **N=23** |
| **URINALYSIS** |  |  |  |  |  |  |  |  |
| **pH Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 27 (87.1) | 32 (84.2) | 26 (89.7) | 33 (94.3) | 19 (95.0) | 23 (92.0) | 15 (88.2) | 19 (82.6) |
| No | 3 (9.7) | 1 (2.6) | 2 (6.9) | 0 (0.0) | 1 (5.0) | 1 (4.0) | 1 (5.9) | 2 (8.7) |
| Missing | 1 (3.2) | 5 (13.2) | 1 (3.4) | 2 (5.7) | 0 (0.0) | 1 (4.0) | 1 (5.9) | 2 (8.7) |
| **pH clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 29 (93.5) | 33 (86.8) | 27 (93.1) | 32 (91.4) | 20 (100.0) | 24 (96.0) | 16 (94.1) | 21 (91.3) |
| Yes | 1 (3.2) | 0 (0.0) | 1 (3.4) | 1 (2.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Missing | 1 (3.2) | 5 (13.2) | 1 (3.4) | 2 (5.7) | 0 (0.0) | 1 (4.0) | 1 (5.9) | 2 (8.7) |
| **Glucose Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 30 (96.8) | 31 (81.6) | 28 (96.6) | 30 (85.7) | 20 (100.0) | 22 (88.0) | 15 (88.2) | 19 (82.6) |
| No | 0 (0.0) | 2 (5.3) | 0 (0.0) | 3 (8.6) | 0 (0.0) | 2 (8.0) | 1 (5.9) | 2 (8.7) |
| Missing | 1 (3.2) | 5 (13.2) | 1 (3.4) | 2 (5.7) | 0 (0.0) | 1 (4.0) | 1 (5.9) | 2 (8.7) |
| **Glucose Clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 28 (90.3) | 32 (84.2) | 27 (93.1) | 32 (91.4) | 20 (100.0) | 24 (96.0) | 16 (94.1) | 19 (82.6) |
| Yes | 2 (6.5) | 1 (2.6) | 1 (3.4) | 1 (2.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (8.7) |
| Missing | 1 (3.2) | 5 (13.2) | 1 (3.4) | 2 (5.7) | 0 (0.0) | 1 (4.0) | 1 (5.9) | 2 (8.7) |
| **Blood Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 26 (83.9) | 32 (84.2) | 22 (75.9) | 32 (91.4) | 16 (80.0) | 23 (92.0) | 14 (82.4) | 20 (87.0) |
| No | 4 (12.9) | 1 (2.6) | 6 (20.7) | 1 (2.9) | 4 (20.0) | 1 (4.0) | 2 (11.8) | 1 (4.3) |
| Missing | 1 (3.2) | 5 (13.2) | 1 (3.4) | 2 (5.7) | 0 (0.0) | 1 (4.0) | 1 (5.9) | 2 (8.7) |
| **Blood Clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 28 (90.3) | 32 (84.2) | 27 (93.1) | 32 (91.4) | 19 (95.0) | 24 (96.0) | 16 (94.1) | 21 (91.3) |
| Yes | 2 (6.5) | 1 (2.6) | 1 (3.4) | 1 (2.9) | 1 (5.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Missing | 1 (3.2) | 5 (13.2) | 1 (3.4) | 2 (5.7) | 0 (0.0) | 1 (4.0) | 1 (5.9) | 2 (8.7) |
| **Protein Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 25 (80.6) | 30 (78.9) | 22 (75.9) | 32 (91.4) | 16 (80.0) | 21 (84.0) | 14 (82.4) | 17 (73.9) |
| No | 5 (16.1) | 3 (7.9) | 6 (20.7) | 1 (2.9) | 4 (20.0) | 3 (12.0) | 2 (11.8) | 4 (17.4) |
| Missing | 1 (3.2) | 5 (13.2) | 1 (3.4) | 2 (5.7) | 0 (0.0) | 1 (4.0) | 1 (5.9) | 2 (8.7) |
| **Protein Clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 29 (93.5) | 31 (81.6) | 26 (89.7) | 32 (91.4) | 19 (95.0) | 24 (96.0) | 16 (94.1) | 21 (91.3) |
| Yes | 1 (3.2) | 2 (5.3) | 2 (6.9) | 1 (2.9) | 1 (5.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Missing | 1 (3.2) | 5 (13.2) | 1 (3.4) | 2 (5.7) | 0 (0.0) | 1 (4.0) | 1 (5.9) | 2 (8.7) |
| **Leucocytes Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 30 (96.8) | 33 (86.8) | 28 (96.6) | 32 (91.4) | 19 (95.0) | 24 (96.0) | 16 (94.1) | 19 (82.6) |
| No | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.9) | 1 (5.0) | 0 (0.0) | 0 (0.0) | 2 (8.7) |
| Missing | 1 (3.2) | 5 (13.2) | 1 (3.4) | 2 (5.7) | 0 (0.0) | 1 (4.0) | 1 (5.9) | 2 (8.7) |
| **Leucocytes Clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 28 (90.3) | 33 (86.8) | 27 (93.1) | 32 (91.4) | 20 (100.0) | 24 (96.0) | 16 (94.1) | 20 (87.0) |
| Yes | 2 (6.5) | 0 (0.0) | 1 (3.4) | 1 (2.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (4.3) |
| Missing | 1 (3.2) | 5 (13.2) | 1 (3.4) | 2 (5.7) | 0 (0.0) | 1 (4.0) | 1 (5.9) | 2 (8.7) |
| **Blood results - n, median (IQR)** |  |  |  |  |  |  |  |  |
| Serum creatinine - umol/L | 31, 74.0 (62.0-84.0) | 38, 75.0 (60.0-88.0) | 29, 84.0 (75.0-99.0) | 35, 77.0 (61.0-87.0) | 20, 78.0 (73.5-95.5) | 25, 76.0 (67.0-85.0) | 17, 88.0 (73.0-100.0) | 23, 75.0 (65.0-81.0) |
| Urea - mmol/L | 30, 5.0 (4.4-5.8) | 38, 5.3 (3.3-6.0) | 28, 5.4 (4.3-6.7) | 34, 4.8 (4.4-5.7) | 20, 4.7 (4.1-6.1) | 23, 4.5 (3.9-5.5) | 17, 5.3 (4.2-6.3) | 23, 5.0 (4.2-5.6) |
| Corrected calcium - mmol/L | 31, 2.4 (2.3-2.5) | 38, 2.4 (2.3-2.4) | 29, 2.4 (2.3-2.4) | 33, 2.4 (2.3-2.5) | 20, 2.3 (2.3-2.4) | 25, 2.3 (2.3-2.4) | 17, 2.4 (2.3-2.4) | 22, 2.3 (2.3-2.4) |
| Albumin - g/L | 31, 41.0 (40.0-44.0) | 38, 42.0 (38.0-44.0) | 29, 41.0 (40.0-43.0) | 34, 42.0 (38.0-44.0) | 20, 40.5 (40.0-43.0) | 25, 43.0 (40.0-45.0) | 17, 41.0 (40.0-44.0) | 22, 44.0 (41.0-45.0) |
| Neutrophils - 10^9/L | 31, 3.6 (2.4-5.2) | 38, 4.6 (3.2-6.6) | 29, 3.8 (2.9-5.5) | 34, 5.3 (3.6-7.9) | 20, 3.6 (2.7-6.8) | 25, 4.2 (3.4-7.5) | 17, 3.7 (3.2-4.5) | 23, 4.3 (3.5-6.7) |
| WBC - 10^9/L | 31, 5.9 (4.3-8.2) | 38, 7.5 (5.5-9.7) | 29, 6.2 (4.6-7.5) | 34, 8.8 (6.5-10.3) | 20, 5.0 (4.5-8.1) | 25, 6.6 (5.4-10.0) | 17, 5.8 (4.5-7.1) | 23, 6.9 (6.2-9.2) |
| ALT - IU/L | 28, 17.0 (11.5-24.0) | 37, 19.0 (13.0-27.0) | 27, 14.0 (10.0-22.0) | 31, 19.0 (13.0-24.0) | 19, 15.0 (10.0-23.0) | 25, 20.0 (16.0-29.0) | 17, 14.0 (9.0-18.0) | 23, 20.0 (16.0-25.0) |
| ALP - IU/L | 29, 86.0 (76.0-99.0) | 36, 94.0 (72.5-110.5) | 28, 87.0 (75.0-99.5) | 31, 94.0 (79.0-121.0) | 19, 88.0 (75.0-100.0) | 24, 97.5 (78.0-118.0) | 16, 92.5 (73.5-99.5) | 22, 96.0 (83.0-106.0) |
| Serum bilirubin - umol/L | 31, 6.0 (5.0-8.0) | 38, 6.0 (5.0-8.0) | 29, 8.0 (7.0-10.0) | 33, 7.0 (6.0-10.0) | 20, 8.0 (6.0-9.0) | 24, 7.0 (6.0-9.0) | 17, 7.0 (6.0-10.0) | 23, 6.0 (6.0-8.0) |
| Potassium - mmol/L | 31, 4.4 (4.3-4.5) | 36, 4.3 (4.0-4.6) | 29, 4.4 (4.1-4.7) | 34, 4.4 (4.0-4.7) | 20, 4.1 (3.9-4.6) | 25, 4.3 (4.1-4.5) | 17, 4.4 (4.1-4.8) | 23, 4.3 (4.1-4.7) |
| Sodium - mmol/L | 31, 140.0 (139.0-142.0) | 37, 138.0 (137.0-141.0) | 29, 140.0 (139.0-141.0) | 34, 139.0 (137.0-140.0) | 20, 139.0 (137.0-140.5) | 25, 139.0 (138.0-140.0) | 17, 141.0 (138.0-143.0) | 23, 139.0 (137.0-140.0) |
| Platelets - 10^9/L | 31, 289.0 (218.0-373.0) | 38, 307.5 (242.0-375.0) | 29, 257.0 (208.0-312.0) | 33, 269.0 (227.0-326.0) | 20, 238.0 (186.0-289.0) | 25, 241.0 (208.0-306.0) | 17, 239.0 (198.0-293.0) | 23, 253.0 (218.0-338.0) |
| Haemoglobin - g/L | 31, 112.0 (103.0-121.0) | 38, 117.0 (107.0-126.0) | 29, 116.0 (109.0-123.0) | 33, 127.0 (117.0-133.0) | 20, 112.5 (105.5-123.0) | 25, 131.0 (120.0-143.0) | 17, 120.0 (111.0-127.0) | 23, 132.0 (122.0-144.0) |
| RBC - 10^12/L | 31, 3.6 (3.3-3.9) | 38, 3.7 (3.4-4.1) | 29, 3.5 (3.4-3.8) | 33, 3.9 (3.7-4.2) | 20, 3.5 (3.1-3.7) | 25, 4.0 (3.9-4.4) | 17, 3.6 (3.2-3.8) | 23, 4.5 (4.0-4.7) |
| AST - IU/L | 23, 20.0 (18.0-25.0) | 25, 22.0 (18.0-25.0) | 19, 19.0 (15.0-20.0) | 24, 20.5 (17.5-24.5) | 11, 19.0 (16.0-23.0) | 19, 23.0 (16.0-27.0) | 11, 17.0 (15.0-19.0) | 13, 22.0 (13.0-26.0) |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  | **Cycle 5** | | **Cycle 6** | | **Cycle 7** | | **Cycle 8** | |
| **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** |
| **N=13** | **N=15** | **N=11** | **N=13** | **N=6** | **N=7** | **N=6** | **N=6** |
| **URINALYSIS** |  |  |  |  |  |  |  |  |
| **pH Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 13 (100.0) | 14 (93.3) | 8 (72.7) | 12 (92.3) | 6 (100.0) | 7 (100.0) | 4 (66.7) | 6 (100.0) |
| No | 0 (0.0) | 1 (6.7) | 1 (9.1) | 1 (7.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Missing | 0 (0.0) | 0 (0.0) | 2 (18.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (33.3) | 0 (0.0) |
| **pH clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 13 (100.0) | 15 (100.0) | 9 (81.8) | 12 (92.3) | 6 (100.0) | 7 (100.0) | 4 (66.7) | 6 (100.0) |
| Yes | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (7.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Missing | 0 (0.0) | 0 (0.0) | 2 (18.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (33.3) | 0 (0.0) |
| **Glucose Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 12 (92.3) | 15 (100.0) | 9 (81.8) | 13 (100.0) | 6 (100.0) | 7 (100.0) | 3 (50.0) | 6 (100.0) |
| No | 1 (7.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Missing | 0 (0.0) | 0 (0.0) | 2 (18.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (50.0) | 0 (0.0) |
| **Glucose Clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 13 (100.0) | 15 (100.0) | 9 (81.8) | 13 (100.0) | 6 (100.0) | 7 (100.0) | 3 (50.0) | 6 (100.0) |
| Yes | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Missing | 0 (0.0) | 0 (0.0) | 2 (18.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (50.0) | 0 (0.0) |
| **Blood Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 11 (84.6) | 13 (86.7) | 9 (81.8) | 12 (92.3) | 6 (100.0) | 7 (100.0) | 3 (50.0) | 6 (100.0) |
| No | 2 (15.4) | 2 (13.3) | 0 (0.0) | 1 (7.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Missing | 0 (0.0) | 0 (0.0) | 2 (18.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (50.0) | 0 (0.0) |
| **Blood Clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 13 (100.0) | 14 (93.3) | 9 (81.8) | 12 (92.3) | 6 (100.0) | 7 (100.0) | 3 (50.0) | 6 (100.0) |
| Yes | 0 (0.0) | 1 (6.7) | 0 (0.0) | 1 (7.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Missing | 0 (0.0) | 0 (0.0) | 2 (18.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (50.0) | 0 (0.0) |
| **Protein Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 8 (61.5) | 12 (80.0) | 7 (63.6) | 11 (84.6) | 5 (83.3) | 7 (100.0) | 3 (50.0) | 6 (100.0) |
| No | 5 (38.5) | 2 (13.3) | 2 (18.2) | 2 (15.4) | 1 (16.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Missing | 0 (0.0) | 1 (6.7) | 2 (18.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (50.0) | 0 (0.0) |
| **Protein Clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 12 (92.3) | 13 (86.7) | 9 (81.8) | 12 (92.3) | 5 (83.3) | 7 (100.0) | 3 (50.0) | 6 (100.0) |
| Yes | 1 (7.7) | 1 (6.7) | 0 (0.0) | 1 (7.7) | 1 (16.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Missing | 0 (0.0) | 1 (6.7) | 2 (18.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (50.0) | 0 (0.0) |
| **Leucocytes Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 12 (92.3) | 14 (93.3) | 9 (81.8) | 10 (76.9) | 6 (100.0) | 7 (100.0) | 3 (50.0) | 5 (83.3) |
| No | 1 (7.7) | 1 (6.7) | 0 (0.0) | 3 (23.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (16.7) |
| Missing | 0 (0.0) | 0 (0.0) | 2 (18.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (50.0) | 0 (0.0) |
| **Leucocytes Clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 13 (100.0) | 14 (93.3) | 9 (81.8) | 12 (92.3) | 6 (100.0) | 7 (100.0) | 3 (50.0) | 6 (100.0) |
| Yes | 0 (0.0) | 1 (6.7) | 0 (0.0) | 1 (7.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Missing | 0 (0.0) | 0 (0.0) | 2 (18.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (50.0) | 0 (0.0) |
| **Blood results - n, median (IQR)** |  |  |  |  |  |  |  |  |
| Serum creatinine - umol/L | 13, 77.0 (68.0-89.0) | 15, 77.0 (66.0-91.0) | 11, 81.0 (66.0-103.0) | 13, 70.0 (58.0-82.0) | 6, 77.0 (68.0-85.0) | 7, 63.0 (56.0-89.0) | 6, 76.0 (68.0-83.0) | 6, 69.5 (61.0-76.0) |
| Urea - mmol/L | 12, 5.0 (4.5-5.4) | 14, 4.9 (3.8-5.5) | 11, 5.3 (4.4-6.5) | 13, 4.8 (4.1-5.7) | 6, 5.4 (4.2-6.2) | 7, 4.9 (3.6-5.3) | 6, 5.3 (3.8-6.3) | 6, 5.1 (4.9-5.9) |
| Corrected calcium - mmol/L | 13, 2.4 (2.3-2.5) | 15, 2.3 (2.2-2.5) | 10, 2.4 (2.3-2.4) | 12, 2.3 (2.3-2.4) | 6, 2.4 (2.3-2.4) | 6, 2.3 (2.3-2.3) | 6, 2.4 (2.4-2.4) | 6, 2.3 (2.3-2.3) |
| Albumin - g/L | 13, 41.0 (40.0-43.0) | 15, 43.0 (36.0-46.0) | 11, 42.0 (39.0-44.0) | 12, 43.5 (39.0-44.0) | 6, 43.0 (40.0-45.0) | 6, 41.5 (31.0-44.0) | 6, 41.5 (39.0-44.0) | 6, 43.5 (33.0-45.0) |
| Neutrophils - 10^9/L | 13, 3.7 (3.1-4.7) | 15, 4.0 (3.8-5.5) | 11, 3.5 (2.9-5.3) | 13, 3.9 (3.4-5.0) | 6, 3.0 (2.6-4.6) | 7, 3.9 (3.2-5.9) | 6, 3.6 (3.4-4.6) | 6, 3.6 (3.1-4.2) |
| WBC - 10^9/L | 13, 5.7 (4.8-6.9) | 15, 7.2 (5.9-8.3) | 11, 6.1 (4.6-7.7) | 13, 6.3 (5.3-9.0) | 6, 4.5 (4.2-7.6) | 7, 7.3 (5.0-9.3) | 6, 5.4 (4.7-7.3) | 6, 6.3 (5.5-7.0) |
| ALT - IU/L | 12, 11.5 (9.0-21.0) | 15, 22.0 (18.0-26.0) | 11, 13.0 (10.0-22.0) | 13, 21.0 (18.0-24.0) | 6, 16.0 (11.0-20.0) | 6, 17.0 (12.0-21.0) | 6, 15.5 (15.0-19.0) | 6, 15.5 (13.0-32.0) |
| ALP - IU/L | 13, 87.0 (82.0-102.0) | 14, 96.0 (81.0-127.0) | 11, 90.0 (68.0-106.0) | 13, 99.0 (84.0-128.0) | 6, 74.5 (72.0-87.0) | 6, 102.5 (83.0-155.0) | 6, 69.0 (65.0-88.0) | 6, 92.5 (73.0-159.0) |
| Serum bilirubin - umol/L | 13, 7.0 (6.0-11.0) | 15, 7.0 (6.0-8.0) | 11, 7.0 (6.0-11.0) | 13, 8.0 (7.0-10.0) | 6, 7.5 (5.0-9.0) | 6, 8.0 (6.0-10.0) | 6, 6.0 (5.0-10.0) | 6, 8.0 (8.0-10.0) |
| Potassium - mmol/L | 13, 4.4 (4.3-4.7) | 15, 4.4 (4.2-4.6) | 11, 4.3 (4.1-4.8) | 13, 4.1 (3.9-4.4) | 6, 4.7 (4.2-4.7) | 7, 4.2 (3.9-4.4) | 6, 4.4 (4.3-4.4) | 6, 4.3 (3.8-4.6) |
| Sodium - mmol/L | 13, 139.0 (138.0-141.0) | 15, 139.0 (137.0-140.0) | 11, 139.0 (136.0-141.0) | 13, 138.0 (138.0-139.0) | 6, 140.5 (139.0-141.0) | 7, 139.0 (136.0-141.0) | 6, 141.0 (139.0-143.0) | 6, 138.0 (137.0-138.0) |
| Platelets - 10^9/L | 13, 230.0 (208.0-264.0) | 15, 256.0 (219.0-356.0) | 11, 227.0 (204.0-269.0) | 13, 231.0 (210.0-310.0) | 6, 274.0 (229.0-284.0) | 7, 241.0 (227.0-336.0) | 6, 263.0 (252.0-270.0) | 6, 257.0 (241.0-284.0) |
| Haemoglobin - g/L | 13, 121.0 (114.0-126.0) | 15, 133.0 (120.0-137.0) | 11, 119.0 (107.0-131.0) | 13, 133.0 (127.0-140.0) | 6, 120.0 (113.0-130.0) | 7, 131.0 (120.0-141.0) | 6, 125.0 (111.0-134.0) | 6, 130.5 (119.0-135.0) |
| RBC - 10^12/L | 13, 3.6 (3.2-3.7) | 15, 4.4 (4.2-4.8) | 11, 3.4 (3.0-3.7) | 13, 4.4 (4.2-4.6) | 6, 3.5 (3.4-3.7) | 7, 4.3 (4.1-4.6) | 6, 3.5 (3.5-3.9) | 6, 4.5 (4.2-4.7) |
| AST - IU/L | 8, 18.0 (15.0-20.0) | 11, 22.0 (16.0-25.0) | 7, 19.0 (12.0-22.0) | 10, 23.0 (20.0-29.0) | 5, 18.0 (18.0-20.0) | 6, 17.5 (16.0-24.0) | 4, 14.0 (11.5-23.5) | 5, 16.0 (15.0-17.0) |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  | **Cycle 9** | | **Cycle 10** | | **Cycle 11** | | **Cycle 12** | |
| **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** |
| **N=3** | **N=1** | **N=2** | **N=1** | **N=2** | **N=0** | **N=2** | **N=0** |
| **URINALYSIS** |  |  |  |  |  |  |  |  |
| **pH Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 3 (100.0) | 1 (100.0) | 2 (100.0) | 1 (100.0) | 2 (100.0) | 0 (.) | 2 (100.0) | 0 (.) |
| No | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| Missing | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| **pH clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 2 (66.7) | 1 (100.0) | 2 (100.0) | 1 (100.0) | 2 (100.0) | 0 (.) | 2 (100.0) | 0 (.) |
| Yes | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| Missing | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| **Glucose Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 3 (100.0) | 1 (100.0) | 2 (100.0) | 1 (100.0) | 2 (100.0) | 0 (.) | 2 (100.0) | 0 (.) |
| No | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| Missing | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| **Glucose Clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 2 (66.7) | 1 (100.0) | 2 (100.0) | 1 (100.0) | 2 (100.0) | 0 (.) | 2 (100.0) | 0 (.) |
| Yes | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| Missing | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| **Blood Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 3 (100.0) | 1 (100.0) | 2 (100.0) | 1 (100.0) | 2 (100.0) | 0 (.) | 2 (100.0) | 0 (.) |
| No | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| Missing | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| **Blood Clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 2 (66.7) | 1 (100.0) | 2 (100.0) | 1 (100.0) | 2 (100.0) | 0 (.) | 2 (100.0) | 0 (.) |
| Yes | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| Missing | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| **Protein Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 2 (66.7) | 1 (100.0) | 1 (50.0) | 1 (100.0) | 2 (100.0) | 0 (.) | 2 (100.0) | 0 (.) |
| No | 1 (33.3) | 0 (0.0) | 1 (50.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| Missing | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| **Protein Clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 3 (100.0) | 1 (100.0) | 2 (100.0) | 1 (100.0) | 2 (100.0) | 0 (.) | 2 (100.0) | 0 (.) |
| Yes | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| Missing | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| **Leucocytes Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 3 (100.0) | 1 (100.0) | 2 (100.0) | 1 (100.0) | 2 (100.0) | 0 (.) | 2 (100.0) | 0 (.) |
| No | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| Missing | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| **Leucocytes Clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 2 (66.7) | 1 (100.0) | 2 (100.0) | 1 (100.0) | 2 (100.0) | 0 (.) | 2 (100.0) | 0 (.) |
| Yes | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| Missing | 1 (33.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| **Blood results - n, median (IQR)** |  |  |  |  |  |  |  |  |
| Serum creatinine - umol/L | 3, 69.0 (65.0-102.0) | 1, 49.0 (49.0-49.0) | 2, 83.0 (71.0-95.0) | 1, 58.0 (58.0-58.0) | 2, 83.5 (74.0-93.0) | - | 2, 77.0 (64.0-90.0) | - |
| Urea - mmol/L | 3, 4.5 (3.6-6.8) | 1, 3.7 (3.7-3.7) | 2, 5.0 (4.0-6.1) | 1, 4.8 (4.8-4.8) | 2, 5.0 (3.5-6.4) | - | 2, 5.0 (4.2-5.9) | - |
| Corrected calcium - mmol/L | 3, 2.4 (2.4-2.4) | 1, 2.2 (2.2-2.2) | 2, 2.4 (2.3-2.4) | 1, 2.3 (2.3-2.3) | 2, 2.4 (2.3-2.4) | - | 2, 2.4 (2.3-2.4) | - |
| Albumin - g/L | 3, 41.0 (34.0-48.0) | 1, 45.0 (45.0-45.0) | 2, 42.5 (40.0-45.0) | 1, 43.0 (43.0-43.0) | 2, 43.0 (41.0-45.0) | - | 2, 40.5 (38.0-43.0) | - |
| Neutrophils - 10^9/L | 3, 3.5 (3.0-8.5) | 1, 3.4 (3.4-3.4) | 2, 5.8 (2.9-8.6) | 1, 2.5 (2.5-2.5) | 2, 7.1 (3.8-10.4) | - | 2, 7.9 (5.2-10.6) | - |
| WBC - 10^9/L | 3, 5.2 (4.6-11.3) | 1, 5.3 (5.3-5.3) | 2, 7.9 (4.9-10.9) | 1, 4.7 (4.7-4.7) | 2, 9.4 (6.1-12.7) | - | 2, 10.1 (7.0-13.2) | - |
| ALT - IU/L | 3, 11.0 (10.0-26.0) | 1, 18.0 (18.0-18.0) | 2, 16.5 (9.0-24.0) | 1, 19.0 (19.0-19.0) | 2, 16.5 (12.0-21.0) | - | 2, 23.5 (22.0-25.0) | - |
| ALP - IU/L | 3, 94.0 (94.0-116.0) | 1, 83.0 (83.0-83.0) | 2, 99.5 (84.0-115.0) | 1, 78.0 (78.0-78.0) | 2, 113.5 (101.0-126.0) | - | 2, 112.0 (97.0-127.0) | - |
| Serum bilirubin - umol/L | 3, 9.0 (6.0-20.0) | 1, 8.0 (8.0-8.0) | 2, 11.0 (7.0-15.0) | 1, 5.0 (5.0-5.0) | 2, 14.5 (6.0-23.0) | - | 2, 8.0 (8.0-8.0) | - |
| Potassium - mmol/L | 3, 4.4 (4.2-4.5) | 1, 4.4 (4.4-4.4) | 2, 4.4 (4.2-4.6) | 1, 4.7 (4.7-4.7) | 2, 4.3 (4.2-4.5) | - | 2, 4.3 (4.0-4.5) | - |
| Sodium - mmol/L | 3, 138.0 (135.0-139.0) | 1, 139.0 (139.0-139.0) | 2, 140.0 (140.0-140.0) | 1, 141.0 (141.0-141.0) | 2, 139.5 (139.0-140.0) | - | 2, 140.5 (140.0-141.0) | - |
| Platelets - 10^9/L | 3, 247.0 (236.0-557.0) | 1, 250.0 (250.0-250.0) | 2, 330.5 (275.0-386.0) | 1, 235.0 (235.0-235.0) | 2, 332.5 (253.0-412.0) | - | 2, 495.0 (277.0-713.0) | - |
| Haemoglobin - g/L | 3, 136.0 (108.0-149.0) | 1, 134.0 (134.0-134.0) | 2, 136.0 (135.0-137.0) | 1, 135.0 (135.0-135.0) | 2, 137.0 (136.0-138.0) | - | 2, 125.0 (120.0-130.0) | - |
| RBC - 10^12/L | 3, 3.5 (3.1-4.2) | 1, 4.1 (4.1-4.1) | 2, 3.8 (3.5-4.0) | 1, 4.1 (4.1-4.1) | 2, 3.8 (3.5-4.1) | - | 2, 3.4 (3.3-3.6) | - |
| AST - IU/L | 2, 20.5 (15.0-26.0) | 1, 20.0 (20.0-20.0) | 2, 19.5 (13.0-26.0) | 1, 20.0 (20.0-20.0) | 2, 21.0 (16.0-26.0) | - | 2, 20.5 (15.0-26.0) | - |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  | **Cycle 13** | | **Cycle 14** | | **Cycle 15** | | **Cycle 16** | |
| **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** |
| **N=1** | **N=0** | **N=1** | **N=0** | **N=1** | **N=0** | **N=1** | **N=0** |
| **URINALYSIS** |  |  |  |  |  |  |  |  |
| **pH Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) |
| No | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| Missing | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| **pH clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) |
| Yes | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| Missing | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| **Glucose Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) |
| No | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| Missing | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| **Glucose Clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) |
| Yes | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| Missing | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| **Blood Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) |
| No | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| Missing | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| **Blood Clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) |
| Yes | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| Missing | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| **Protein Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) |
| No | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| Missing | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| **Protein Clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) |
| Yes | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| Missing | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| **Leucocytes Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) |
| No | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| Missing | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| **Leucocytes Clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) |
| Yes | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| Missing | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| **Blood results - n, median (IQR)** |  |  |  |  |  |  |  |  |
| Serum creatinine - umol/L | 1, 92.0 (92.0-92.0) | - | 1, 98.0 (98.0-98.0) | - | 1, 94.0 (94.0-94.0) | - | 1, 111.0 (111.0-111.0) | - |
| Urea - mmol/L | 1, 5.6 (5.6-5.6) | - | 1, 5.2 (5.2-5.2) | - | 1, 5.8 (5.8-5.8) | - | 1, 7.0 (7.0-7.0) | - |
| Corrected calcium - mmol/L | 1, 2.4 (2.4-2.4) | - | 1, 2.4 (2.4-2.4) | - | 1, 2.3 (2.3-2.3) | - | 1, 2.5 (2.5-2.5) | - |
| Albumin - g/L | 1, 45.0 (45.0-45.0) | - | 1, 45.0 (45.0-45.0) | - | 1, 43.0 (43.0-43.0) | - | 1, 46.0 (46.0-46.0) | - |
| Neutrophils - 10^9/L | 1, 7.2 (7.2-7.2) | - | 1, 10.1 (10.1-10.1) | - | 1, 8.6 (8.6-8.6) | - | 1, 9.7 (9.7-9.7) | - |
| WBC - 10^9/L | 1, 9.8 (9.8-9.8) | - | 1, 12.6 (12.6-12.6) | - | 1, 10.9 (10.9-10.9) | - | 1, 12.7 (12.7-12.7) | - |
| ALT - IU/L | 1, 9.0 (9.0-9.0) | - | 1, 9.0 (9.0-9.0) | - | 1, 9.0 (9.0-9.0) | - | 1, 9.0 (9.0-9.0) | - |
| ALP - IU/L | 1, 134.0 (134.0-134.0) | - | 1, 140.0 (140.0-140.0) | - | 1, 154.0 (154.0-154.0) | - | 1, 180.0 (180.0-180.0) | - |
| Serum bilirubin - umol/L | 1, 26.0 (26.0-26.0) | - | 1, 18.0 (18.0-18.0) | - | 1, 17.0 (17.0-17.0) | - | 1, 31.0 (31.0-31.0) | - |
| Potassium - mmol/L | 1, 3.6 (3.6-3.6) | - | 1, 4.3 (4.3-4.3) | - | 1, 4.2 (4.2-4.2) | - | 1, 4.2 (4.2-4.2) | - |
| Sodium - mmol/L | 1, 138.0 (138.0-138.0) | - | 1, 139.0 (139.0-139.0) | - | 1, 142.0 (142.0-142.0) | - | 1, 138.0 (138.0-138.0) | - |
| Platelets - 10^9/L | 1, 440.0 (440.0-440.0) | - | 1, 487.0 (487.0-487.0) | - | 1, 417.0 (417.0-417.0) | - | 1, 442.0 (442.0-442.0) | - |
| Haemoglobin - g/L | 1, 137.0 (137.0-137.0) | - | 1, 139.0 (139.0-139.0) | - | 1, 139.0 (139.0-139.0) | - | 1, 148.0 (148.0-148.0) | - |
| RBC - 10^12/L | 1, 3.9 (3.9-3.9) | - | 1, 4.1 (4.1-4.1) | - | 1, 4.0 (4.0-4.0) | - | 1, 4.2 (4.2-4.2) | - |
| AST - IU/L | 1, 12.0 (12.0-12.0) | - | 1, 85.0 (85.0-85.0) | - | 1, 15.0 (15.0-15.0) | - | - | - |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  | **Cycle 17** | | **Cycle 18** | |  |  |  |  |
| **Olaparib** | **Placebo** | **Olaparib** | **Placebo** |  |  |  |  |
| **N=1** | **N=0** | **N=1** | **N=0** |  |  |  |  |
| **URINALYSIS** |  |  |  |  |  |  |  |  |
| **pH Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) |  |  |  |  |
| No | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |  |  |  |  |
| Missing | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |  |  |  |  |
| **pH clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) |  |  |  |  |
| Yes | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |  |  |  |  |
| Missing | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |  |  |  |  |
| **Glucose Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) |  |  |  |  |
| No | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |  |  |  |  |
| Missing | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |  |  |  |  |
| **Glucose Clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) |  |  |  |  |
| Yes | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |  |  |  |  |
| Missing | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |  |  |  |  |
| **Blood Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) |  |  |  |  |
| No | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |  |  |  |  |
| Missing | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |  |  |  |  |
| **Blood Clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) |  |  |  |  |
| Yes | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |  |  |  |  |
| Missing | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |  |  |  |  |
| **Protein Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) |  |  |  |  |
| No | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |  |  |  |  |
| Missing | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |  |  |  |  |
| **Protein Clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) |  |  |  |  |
| Yes | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |  |  |  |  |
| Missing | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |  |  |  |  |
| **Leucocytes Normal - N (%)** |  |  |  |  |  |  |  |  |
| Yes | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) |  |  |  |  |
| No | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |  |  |  |  |
| Missing | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |  |  |  |  |
| **Leucocytes Clinically significant - N (%)** |  |  |  |  |  |  |  |  |
| No | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) |  |  |  |  |
| Yes | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |  |  |  |  |
| Missing | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |  |  |  |  |
| **Blood results - n, median (IQR)** |  |  |  |  |  |  |  |  |
| Serum creatinine - umol/L | 1, 98.0 (98.0-98.0) | - | 1, 92.0 (92.0-92.0) | - |  |  |  |  |
| Urea - mmol/L | 1, 8.7 (8.7-8.7) | - | 1, 5.0 (5.0-5.0) | - |  |  |  |  |
| Corrected calcium - mmol/L | 1, 2.3 (2.3-2.3) | - | 1, 2.3 (2.3-2.3) | - |  |  |  |  |
| Albumin - g/L | 1, 46.0 (46.0-46.0) | - | 1, 43.0 (43.0-43.0) | - |  |  |  |  |
| Neutrophils - 10^9/L | 1, 9.2 (9.2-9.2) | - | 1, 8.7 (8.7-8.7) | - |  |  |  |  |
| WBC - 10^9/L | 1, 11.9 (11.9-11.9) | - | 1, 11.4 (11.4-11.4) | - |  |  |  |  |
| ALT - IU/L | 1, 11.0 (11.0-11.0) | - | 1, 9.0 (9.0-9.0) | - |  |  |  |  |
| ALP - IU/L | 1, 187.0 (187.0-187.0) | - | 1, 210.0 (210.0-210.0) | - |  |  |  |  |
| Serum bilirubin - umol/L | 1, 18.0 (18.0-18.0) | - | 1, 17.0 (17.0-17.0) | - |  |  |  |  |
| Potassium - mmol/L | 1, 4.3 (4.3-4.3) | - | 1, 4.4 (4.4-4.4) | - |  |  |  |  |
| Sodium - mmol/L | 1, 140.0 (140.0-140.0) | - | 1, 139.0 (139.0-139.0) | - |  |  |  |  |
| Platelets - 10^9/L | 1, 555.0 (555.0-555.0) | - | 1, 515.0 (515.0-515.0) | - |  |  |  |  |
| Haemoglobin - g/L | 1, 151.0 (151.0-151.0) | - | 1, 144.0 (144.0-144.0) | - |  |  |  |  |
| RBC - 10^12/L | 1, 4.4 (4.4-4.4) | - | 1, 4.1 (4.1-4.1) | - |  |  |  |  |
| AST - IU/L | - | - | - | - |  |  |  |  |

Table 6: Collection of translational blood samples at disease progression or end of Cycle 18

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 6 : Collection of translational blood samples at disease progression or end of cycle 18** | **At disease progression** | | **At end of cycle 18 (if not progressed)-THERE IS NO VARIABLE FOR THIS** | |
|  | **Olaparib** | **Placebo** |  |  |
|  | **N=30** | **N=33** | **N=0** | **N=0** |
| **Blood sample was taken for translational purposes - N (%)** |  |  |  |  |
| Yes | 15 (50.0) | 13 (39.4) |  |  |
| No | 15 (50.0) | 20 (60.6) |  |  |
| Missing | 0 (0.0) | 0 (0.0) |  |  |

Table 7: Cardiac assessment

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 7 : Cardiac assessment** | **Cycle 3** | | **30 days post treatment** | |
| **Olaparib** | **Placebo** | **Olaparib** | **Placebo** |
| **N=20** | **N=25** | **N=9** | **N=6** |
| **ECG Resting QTc - n, median(IQR)** | 18, 430.5 (407-438) | 22, 433 (400-447) | 8, 437 (424-440) | 3, 432 (358-468) |

Table 7b: Line listing of patients with prolonged QTc (>470msec)

|  |  |  |  |
| --- | --- | --- | --- |
| Trial Number | End of Cycle 3 | 30 days post treatment | Allocation |
| 57906 | 479 |  | Placebo |
| 67003 | 484 |  | Placebo |

Table 8: Baseline toxicities

| **Table 8: Baseline toxicities** | Olaparib (N=31) | | | | | | | | | | Placebo (N=38) | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Grade reported (N) | | | | | | | | | | Grade reported (N) | | | | | | | | | |
| 1 | % | 2 | % | 3 | % | 4 | % | 3+ | % | 1 | % | 2 | % | 3 | % | 4 | % | 3+ | % |
| **Blood and lymphatic system disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Anaemia | 6 | 19.4% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 11 | 28.9% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Lymphopenia | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Neutropenia | 2 | 6.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Thrombocytopenia | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Cardiac disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Tachycardia | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 4 | 10.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Atrial fibrillation | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Palpitations | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Sinus bradycardia | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Ear and labyrinth disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Hypoacusis | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Tinnitus | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Eye disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Lacrimation increased | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Gastrointestinal disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Abdominal pain | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Constipation | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 4 | 10.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Dry mouth | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Dyspepsia | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Flatulence | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Mucosal inflammation | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Nausea | 3 | 9.7% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Vomiting | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Dysphagia | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Gastrooesophageal reflux disease | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Heartburn | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Loose stools | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **General disorders and administration site conditions** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Fatigue | 11 | 35.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 10 | 26.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Oedema peripheral | 2 | 6.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Chest pain | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Influenza like illness | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Non cardiac pain | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Pain | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Infections and infestations** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Upper respiratory infection | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Urinary tract infection | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Balanitis candida | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Oral candidiasis | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Investigations** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Blood alkaline phosphatase | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Blood alkaline phosphatase increased | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Blood creatinine increased | 2 | 6.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Gamma-glutamyltransferase increased | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| White blood cell count | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Metabolism and nutrition disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Anorexia | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Hyponatraemia | 2 | 6.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Altered taste | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Hypercalcaemia | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Musculoskeletal and connective tissue disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Arthralgia | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Back pain | 1 | 3.2% | 1 | 3.2% | 1 | 3.2% | 0 | 0.0% | 1 | 3.2% | 2 | 5.3% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Arthritis | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Hip pain | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Muscle weakness | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Musculoskeletal chest pain | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Myalgia | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Neck pain | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Pain in extremity | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Pain left femur area.** | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Pruritus** | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Nervous system disorders |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Dizziness | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Dysgeusia | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Headache | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Mental impairment | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Neuropathy peripheral | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Paraesthesia | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Restless legs syndrome** | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Psychiatric disorders |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Insomnia | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Agitation | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Depression | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Head banging | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Respiratory, thoracic and mediastinal disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Coughing | 2 | 6.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 4 | 10.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Dyspnoea | 6 | 19.4% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 8 | 21.1% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| Chronic obstructive pulmonary disease | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Dysphonia | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Epistaxis | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Hiccups | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Nasal discomfort | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Skin and subcutaneous tissue disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Alopecia | 2 | 6.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Night sweats | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Vascular disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Hypertension | 0 | 0.0% | 1 | 3.2% | 1 | 3.2% | 0 | 0.0% | 1 | 3.2% | 4 | 10.5% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Vascular disorders | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Embolism | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| Orthostatic hypotension | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |

Table 9: Worst Reported Toxicities overall (Cycle 1 to 30 days post treatment)

| **Table 9: Worst Reported Toxicities overall (Cycle 1 to 30 days post treatment)** | Olaparib (N=31) | | | | | | | | | | Placebo (N=38) | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Grade reported (N) | | | | | | | | | | Grade reported (N) | | | | | | | | | |
| 1 | % | 2 | % | 3 | % | 4 | % | 3+ | % | 1 | % | 2 | % | 3 | % | 4 | % | 3+ | % |
| **Blood and lymphatic system disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Anaemia | 10 | 32.3% | 5 | 16.1% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 9 | 23.7% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Lymphopenia | 1 | 3.2% | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 1 | 3.2% | 2 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Neutropenia | 3 | 9.7% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Thrombocytopenia | 3 | 9.7% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Leukopenia | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Cardiac disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Tachycardia | 2 | 6.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Atrial fibrillation | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Palpitations | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Sinus bradycardia | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Ear and labyrinth disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Hypoacusis | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Tinnitus | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Eye disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Blurred vision | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| Eye disorder | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Lacrimation increased | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Gastrointestinal disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Abdominal pain | 2 | 6.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Constipation | 3 | 9.7% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 3 | 7.9% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Diarrhoea | 4 | 12.9% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 6 | 15.8% | 0 | 0.0% | 2 | 5.2% | 0 | 0.0% | 2 | 5.2% |
| Dry mouth | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 4 | 10.5% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Dyspepsia | 3 | 9.7% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 7 | 18.4% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Flatulence | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 5 | 13.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Mucosal inflammation | 2 | 6.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Nausea | 13 | 41.9% | 4 | 12.9% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 7 | 18.4% | 4 | 10.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Vomiting | 4 | 12.9% | 3 | 9.7% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 3 | 7.9% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Bloating | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Blocked stent | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Device occlusion | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Dysphagia | 1 | 3.2% | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 1 | 3.2% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Faeces pale | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Gastrooesophageal reflux disease | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Heartburn | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Loss of appetite | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| **General disorders and administration site conditions** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Fatigue | 16 | 51.6% | 4 | 12.9% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 18 | 47.4% | 7 | 18.4% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Fever | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Oedema peripheral | 3 | 9.7% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 4 | 10.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Ankle swelling | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Chest pain | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Edema limbs | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Fatigue | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Influenza like illness | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Pain | 0 | 0.0% | 2 | 6.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 3 | 7.9% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Infections and infestations** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Lower respiratory infection | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Upper respiratory infection | 2 | 6.5% | 2 | 6.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 3 | 7.9% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Urinary tract infection | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Balanitis candida | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Chest infection | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Herpes dermatitis | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Oral candidiasis | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Pneumonia | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 0 | 0.0% | 2 | 5.3% |
| Sinusitis | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Skin infection | 0 | 0.0% | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Investigations** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Blood alkaline phosphatase | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 4 | 10.4% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Blood alkaline phosphatase increased | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Blood creatinine | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Blood creatinine increased | 2 | 6.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Blood glucose increased | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Gamma-glutamyltransferase increased | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Sputum abnormal | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Weight decreased | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| White blood cell count | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| White blood cell count increased | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Metabolism and nutrition disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Anorexia | 8 | 25.8% | 3 | 9.7% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 7 | 18.4% | 5 | 13.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Hyponatraemia | 1 | 3.2% | 1 | 3.2% | 1 | 3.2% | 0 | 0.0% | 1 | 3.2% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| Decreased appetite | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| Hyperkalaemia | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Hypoalbuminaemia | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Hypokalemia | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Loose stools | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Musculoskeletal and connective tissue disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Arthralgia | 2 | 6.5% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Back pain | 2 | 6.5% | 1 | 3.2% | 2 | 6.5% | 0 | 0.0% | 2 | 6.5% | 6 | 15.8% | 2 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Arthritis | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Chest wall pain | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Hip pain | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Muscle weakness | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Musculoskeletal chest pain | 1 | 3.2% | 3 | 9.7% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 5 | 13.2% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| Musculoskeletal disorder | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Musculoskeletal pain | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Myalgia | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Pain in extremity | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Rheumatoid arthritis | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Right arm ache | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Neoplasms benign, malignant and unspecified (incl cysts and polyps)** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Pruritus | 2 | 6.5% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Pathological fracture imminent | 0 | 0.0% | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Nervous system disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Dizziness | 4 | 12.9% | 2 | 6.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 3 | 7.9% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Dysgeusia | 2 | 6.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Headache | 4 | 12.9% | 1 | 3.2% | 1 | 3.2% | 0 | 0.0% | 1 | 3.2% | 5 | 13.2% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| Headache | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| Mental impairment | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Neuropathy peripheral | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Paraesthesia | 2 | 6.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Psychiatric disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Insomnia | 2 | 6.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 5 | 13.2% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Agitation | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Confusional state | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Depression | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Head banging | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Renal and urinary disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Micturition urgency | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Pollakiuria | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Reproductive system and breast disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Night sweats | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Respiratory, thoracic and mediastinal disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Coughing | 11 | 35.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 16 | 42.1% | 5 | 13.2% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| Dyspnoea | 10 | 32.3% | 2 | 6.5% | 1 | 3.2% | 0 | 0.0% | 1 | 3.2% | 10 | 26.3% | 4 | 10.5% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| Nasopharyngitis | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Pneumonitis | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Stomatitis | 1 | 3.2% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 'chest tightness'. sob | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Allergic rhinitus | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Chronic obstructive pulmonary disease | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Coughed up blood x 2 | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| Dysphonia | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Epistaxis | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Hiccups | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Nasal discomfort | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Pleuritic pain | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Productive cough | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Respiratory tract haemorrhage | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| Sputum discoloured | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| White frothy sputum/cough | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Skin and subcutaneous tissue disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Alopecia | 3 | 9.7% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Blisters | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Erythema | 1 | 3.2% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Rash | 4 | 12.9% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Dry skin | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Pain of skin | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Psoriasis | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Right skin leg pain | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Vascular disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Hot flushes | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Hypertension | 1 | 3.2% | 1 | 3.2% | 1 | 3.2% | 0 | 0.0% | 1 | 3.2% | 3 | 7.9% | 5 | 13.2% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| Vascular disorders | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Embolism | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| Orthostatic hypotension | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |

Table 10: Emerging toxicities (not present at baseline) overall (Cycle 1 to 30 days post treatment)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 10: Emerging toxicities (not present at baseline) overall (Cycle 1 to 30 days post treatment)** | Olaparib (N=31) | | | | | | | | | | Placebo (N=38) | | | | | | | | | |
| Grade reported (N) | | | | | | | | | | Grade reported (N) | | | | | | | | | |
| 1 | % | 2 | % | 3 | % | 4 | % | 3+ | % | 1 | % | 2 | % | 3 | % | 4 | % | 3+ | % |
| **Blood and lymphatic system disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Anaemia | 9 | 29.0% | 6 | 19.4% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 12 | 31.6% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Lymphopenia | 1 | 3.2% | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 1 | 3.2% | 2 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Neutropenia | 4 | 12.9% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Thrombocytopenia | 3 | 9.7% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Leukopenia | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Cardiac disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Tachycardia | 2 | 6.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 5 | 13.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Ear and labyrinth disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Hypoacusis | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Tinnitus | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Eye disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Blurred vision | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| Eye disorder | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Gastrointestinal disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Abdominal pain | 2 | 6.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Constipation | 3 | 9.7% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 5 | 13.2% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Diarrhoea | 4 | 12.9% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 6 | 15.8% | 0 | 0.0% | 2 | 5.2% | 0 | 0.0% | 2 | 5.2% |
| Dry mouth | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 4 | 10.5% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Dyspepsia | 3 | 9.7% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 7 | 18.4% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Flatulence | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 5 | 13.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Mucosal inflammation | 2 | 6.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Nausea | 13 | 41.9% | 4 | 12.9% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 7 | 18.4% | 4 | 10.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Vomiting | 4 | 12.9% | 3 | 9.7% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 3 | 7.9% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Bloating | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Device occlusion | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Dysphagia | 0 | 0.0% | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 1 | 3.2% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Faeces pale | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Gastrooesophageal reflux disease | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Loss of appetite | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| **General disorders and administration site conditions** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Fatigue | 16 | 51.6% | 4 | 12.9% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 18 | 47.4% | 7 | 18.4% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Fever | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Oedema peripheral | 3 | 9.7% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 4 | 10.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Ankle swelling | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Edema limbs | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Fatigue | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Pain | 0 | 0.0% | 2 | 6.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Infections and infestations** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Lower respiratory infection | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Upper respiratory infection | 2 | 6.5% | 2 | 6.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 3 | 7.9% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Urinary tract infection | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Chest infection | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Herpes dermatitis | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Pneumonia | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 0 | 0.0% | 2 | 5.3% |
| Sinusitis | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Skin infection | 0 | 0.0% | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Investigations** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Alkaline phosphate | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Blood creatinine | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Blood creatinine increased | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Blood glucose increased | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Gct increased | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Sputum abnormal | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Weight decreased | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| White blood cell count increased | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Metabolism and nutrition disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Anorexia | 8 | 25.8% | 3 | 9.7% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 7 | 18.4% | 5 | 13.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Hyponatraemia | 1 | 3.2% | 1 | 3.2% | 1 | 3.2% | 0 | 0.0% | 1 | 3.2% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| Decreased appetite | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| Hyperkalaemia | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Hypoalbuminaemia | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Hypokalemia | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Musculoskeletal and connective tissue disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Arthralgia | 2 | 6.5% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Back pain | 2 | 6.5% | 1 | 3.2% | 2 | 6.5% | 0 | 0.0% | 2 | 6.5% | 6 | 15.8% | 2 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Chest wall pain | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Hip pain | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Muscle weakness | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Musculoskeletal chest pain | 0 | 0.0% | 3 | 9.7% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 4 | 10.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Musculoskeletal disorder | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Musculoskeletal pain | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Pain in extremity | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Rheumatoid arthritis | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Right arm ache | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Neoplasms benign, malignant and unspecified (incl cysts and polyps)** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Pruritus | 2 | 6.5% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Pathological fracture imminent | 0 | 0.0% | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Nervous system disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Dizziness | 4 | 12.9% | 2 | 6.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 3 | 7.9% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Dysgeusia | 2 | 6.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Headache | 4 | 12.9% | 1 | 3.2% | 1 | 3.2% | 0 | 0.0% | 1 | 3.2% | 5 | 13.2% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| Headache | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| Paraesthesia | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Psychiatric disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Insomnia | 2 | 6.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 5 | 13.2% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Confusional state | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Renal and urinary disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Micturition urgency | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Pollakiuria | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Respiratory, thoracic and mediastinal disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Coughing | 11 | 35.5% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 16 | 42.1% | 5 | 13.2% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| Dyspnoea | 10 | 32.3% | 2 | 6.5% | 1 | 3.2% | 0 | 0.0% | 1 | 3.2% | 10 | 26.3% | 4 | 10.5% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| Nasopharyngitis | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Pneumonitis | 0 | 0.0% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Stomatitis | 1 | 3.2% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| 'chest tightness'. sob | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Allergic rhinitus | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Dysphonia | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Pleuritic pain | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Productive cough | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Respiratory tract haemorrhage | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| Sputum discoloured | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Skin and subcutaneous tissue disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Alopecia | 3 | 9.7% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Blisters | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Erythema | 1 | 3.2% | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Rash | 4 | 12.9% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 2 | 5.3% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Dry skin | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Pain of skin | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Psoriasis | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Right skin leg pain | 1 | 3.2% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| **Vascular disorders** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Hot flushes | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Hypertension | 1 | 3.2% | 1 | 3.2% | 1 | 3.2% | 0 | 0.0% | 1 | 3.2% | 3 | 7.9% | 5 | 13.2% | 1 | 2.6% | 0 | 0.0% | 1 | 2.6% |
| Vascular disorders | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 2.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |

Table 11: Radiological disease assessment

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 11 : Radiological disease assessment** | **Baseline** | | **Cycle 2** | | **Cycle 4** | | **Cycle 6** | |
| **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** |
| **N=32** | **N=38** | **N=29** | **N=35** | **N=19** | **N=23** | **N=12** | **N=13** |
| **Longest Diameter of Target Tumours - n, median (IQR)** |  |  |  |  |  |  |  |  |
| Primary tumour | 28, 32.5 (22.5-42.5) | 33, 38 (24-48) | 25, 38 (25.5-47) | 31, 38 (25-55) | 16, 42.5 (32-51) | 20, 38.5 (19.5-49) | 9, 50 (33-57) | 12, 37 (17-49.5) |
| Lymph node | 5, 16 (15-18) | 9, 16 (13-19) | 5, 15 (14-16) | 8, 19.5 (16.5-20.5) | 4, 12.5 (11.5-15) | 5, 18 (17-21) | 3, 13 (12-19) | 2, 18.5 (13-24) |
| Brain | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) |
| Bone | 1, 39 (39-39) | 0, . (.-.) | 1, 38 (38-38) | 0, . (.-.) | 1, 38 (38-38) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) |
| Liver | 2, 16 (16-16) | 1, 26 (26-26) | 1, 18 (18-18) | 1, 22 (22-22) | 1, 21 (21-21) | 1, 24 (24-24) | 0, . (.-.) | 1, 24 (24-24) |
| Adrenal glands | 2, 47.5 (36-59) | 2, 15.5 (11-20) | 2, 42.5 (31-54) | 2, 14 (9-19) | 2, 41 (28-54) | 1, 11 (11-11) | 1, 30 (30-30) | 1, 20 (20-20) |
| Lung | 1, 39 (39-39) | 2, 65.5 (54-77) | 1, 27 (27-27) | 2, 41.5 (15-68) | 1, 28.5 (22-35) | 1, 16 (16-16) | 1, 11 (11-11) | 0, . (.-.) |
| Anterior mediastinum | 1, 30 (30-30) | 0, . (.-.) | 1, 42 (42-42) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) |
| Paracardiac chest wall | 0, . (.-.) | 1, 38 (38-38) | 0, . (.-.) | 1, 47 (47-47) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) |
| Spleen | 0, . (.-.) | 1, 17 (17-17) | 0, . (.-.) | 1, 21 (21-21) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) |
| **Sum of Longest Diameters - n, median (IQR)** | 30, 53.5 (30-69) | 36, 44.5 (33-62.5) | 27, 58 (27-73) | 33, 47 (32-73) | 18, 61.5 (43-79) | 21, 46 (32-60) | 10, 60 (28-80) | 12, 44 (31-63.5) |
| **Minimum SLD - n, median (IQR)** | NA | NA | 27, 52 (24-67) | 33, 43 (30-62) | 18, 58 (37-69) | 21, 42 (30-57) | 10, 48 (27-61) | 12, 41.5 (27.5-60) |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  | **Cycle 8** | | **Cycle 10** | | **Cycle 12** | | **Cycle 14** | |
| **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** |
| **N=6** | **N=7** | **N=2** | **N=1** | **N=2** | **N=0** | **N=1** | **N=0** |
| **Longest Diameter of Target Tumours - n, median (IQR)** |  |  |  |  |  |  |  |  |
| Primary tumour | 3, 28 (14-60) | 6, 45 (26-48) | 2, 21 (14-28) | 1, 44 (44-44) | 2, 24.5 (15-34) | 0, . (.-.) | 1, 15 (15-15) | 0, . (.-.) |
| Lymph node | 0, . (.-.) | 1, 35 (35-35) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) |
| Brain | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) |
| Bone | 1, 43 (43-43) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) |
| Liver | 1, 38 (38-38) | 1, 40 (40-40) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) |
| Adrenal glands | 1, 27 (27-27) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) |
| Lung | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) |
| Anterior mediastinum | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) |
| Paracardiac chest wall | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) |
| Spleen | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) |
| **Sum of Longest Diameters - n, median (IQR)** | 4, 57.5 (21-99.5) | 6, 63.5 (45-88) | 2, 21 (14-28) | 1, 44 (44-44) | 2, 24.5 (15-34) | 0, . (.-.) | 1, 15 (15-15) | 0, . (.-.) |
| **Minimum SLD - n, median (IQR)** | 4, 20.5 (13-47) | 6, 52 (30-69) | 2, 20.5 (14-27) | 1, 25 (25-25) | 2, 20.5 (14-27) | 0, . (.-.) | 1, 14 (14-14) | 0, . (.-.) |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |
|  | **Cycle 16** | | **Cycle 18** | |  |  |  |  |
| **Olaparib** | **Placebo** | **Olaparib** | **Placebo** |  |  |  |  |
| **N=1** | **N=0** | **N=1** | **N=0** |  |  |  |  |
| **Longest Diameter of Target Tumours - n, median (IQR)** |  |  |  |  |  |  |  |  |
| Primary tumour | 1, 14 (14-14) | 0, . (.-.) | 1, 14 (14-14) | 0, . (.-.) |  |  |  |  |
| Lymph node | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) |  |  |  |  |
| Brain | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) |  |  |  |  |
| Bone | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) |  |  |  |  |
| Liver | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) |  |  |  |  |
| Adrenal glands | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) |  |  |  |  |
| Lung | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) |  |  |  |  |
| Anterior mediastinum | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) |  |  |  |  |
| Paracardiac chest wall | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) |  |  |  |  |
| Spleen | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) | 0, . (.-.) |  |  |  |  |
| **Sum of Longest Diameters - n, median (IQR)** | 1, 14 (14-14) | 0, . (.-.) | 1, 14 (14-14) | 0, . (.-.) |  |  |  |  |
| **Minimum SLD - n, median (IQR)** | 1, 14 (14-14) | 0, . (.-.) | 1, 14 (14-14) | 0, . (.-.) |  |  |  |  |

Table 12: Objective Response

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 12 : Objective Response** | **Overall at end of Cycle 2** | **Cycle 2** | | **Cycle 4** | | **Cycle 6** | | **Cycle 8** | |  |
| **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** |  |
| **N=64** | **N=29** | **N=35** | **N=19** | **N=23** | **N=12** | **N=13** | **N=6** | **N=6** |  |
| RECIST assessment not done | 1 (1.6) | 1 (3.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (8.3) | 0 (0.0) | 2 (33.3) | 0 (0.0) |  |
| **Response of target lesions - N (%)** |  |  |  |  |  |  |  |  |  |  |
| Complete response | 0 (0) | 0 (0.0) | 0 (0.0) | 1 (5.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |  |
| Partial response | 2 (3.1) | 0 (0.0) | 2 (5.7) | 0 (0.0) | 3 (13.0) | 1 (8.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |  |
| Stable disease | 43 (67.2) | 20 (69.0) | 23 (65.7) | 14 (73.7) | 14 (60.9) | 6 (50.0) | 8 (61.5) | 2 (33.3) | 2 (33.3) |  |
| Progressive disease | 14 (21.9) | 6 (20.7) | 8 (22.9) | 3 (15.8) | 4 (17.4) | 3 (25.0) | 4 (30.8) | 2 (33.3) | 4 (66.7) |  |
| Not evaluable | 1 (1.6) | 1 (3.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |  |
| No target lesions at baseline | 3 (4.7) | 1 (3.4) | 2 (5.7) | 1 (5.3) | 2 (8.7) | 1 (8.3) | 1 (7.7) | 0 (0.0) | 0 (0.0) |  |
| **Response of non-target lesions - N (%)** |  |  |  |  |  |  |  |  |  |  |
| Complete response | 3 (4.7) | 0 (0.0) | 3 (10.3) | 0 (0.0) | 1 (5.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (16.7) |  |
| Non-CR/Non-PD | 31 (48.4) | 16 (55.2) | 15 (51.7) | 10 (52.6) | 10 (52.6) | 2 (16.7) | 8 (66.7) | 2 (33.3) | 1 (16.7) |  |
| Progressive disease | 9 (14.1) | 3 (10.3) | 6 (20.7) | 2 (10.5) | 5 (26.3) | 4 (33.3) | 2 (16.7) | 0 (0.0) | 3 (50.0) |  |
| Not evaluable | 3 (4.7) | 2 (6.9) | 1 (3.4) | 1 (5.3) | 1 (5.3) | 1 (8.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |  |
| No non-target lesions at baseline | 17 (26.6) | 7 (24.1) | 10 (34.5) | 6 (31.6) | 6 (31.6) | 4 (33.3) | 3 (25.0) | 1 (16.7) | 1 (16.7) |  |
| Missing | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (16.7) | 0 (0.0) |  |
| **Overall response - N (%)** |  |  |  |  |  |  |  |  |  |  |
| Complete response | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |  |
| Partial response | 1 (1.6) | 0 (0.0) | 1 (3.4) | 1 (5.3) | 2 (10.5) | 1 (8.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |  |
| Stable disease | 42 (65.6) | 20 (69.0) | 22 (75.9) | 15 (78.9) | 12 (63.2) | 3 (25.0) | 7 (58.3) | 2 (33.3) | 1 (16.7) |  |
| Progressive disease | 19 (29.7) | 7 (24.1) | 12 (41.4) | 3 (15.8) | 9 (47.4) | 7 (58.3) | 5 (41.7) | 2 (33.3) | 5 (83.3) |  |
| Not evaluable | 1 (1.6) | 1 (3.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (8.3) | 0 (0.0) | 0 (0.0) |  |
|  |  |  |  |  |  |  |  |  |  |  |
|  | **Cycle 10** | | **Cycle 12** | | **Cycle 14** | | **Cycle 16** | | **Cycle 18** | |
| **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** |
| **N=2** | **N=1** | **N=2** | **N=0** | **N=1** | **N=0** | **N=1** | **N=0** | **N=1** | **N=0** |
| RECIST assessment not done | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| **Response of target lesions - N (%)** |  |  |  |  |  |  |  |  |  |  |
| Complete response | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| Partial response | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| Stable disease | 2 (100.0) | 0 (0.0) | 1 (50.0) | 0 (.) | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) | 1 (100.0) | 0 (.) |
| Progressive disease | 0 (0.0) | 1 (100.0) | 1 (50.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| Not evaluable | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| No target lesions at baseline | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) | 0 (0.0) | 0 (.) |
| **Response of non-target lesions - N (%)** |  |  |  |  |  |  |  |  |  |  |
| Complete response | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Non-CR/Non-PD | 1 (50.0) | 1 (50.0) | 1 (50.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) |
| Progressive disease | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Not evaluable | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| No non-target lesions at baseline | 1 (50.0) | 0 (0.0) | 1 (50.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Missing | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| **Overall response - N (%)** |  |  |  |  |  |  |  |  |  |  |
| Complete response | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Partial response | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Stable disease | 2 (100.0) | 0 (0.0) | 1 (50.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) | 1 (100.0) | 0 (0.0) |
| Progressive disease | 0 (0.0) | 1 (50.0) | 1 (50.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Not evaluable | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |

Table 13: Progression-free and overall survival

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 13: Progression free and overall survival** | **Olaparib** | **Placebo** | **HR (80% for PFS; 95% CI for OS)** | **p-value1** |
|  |  |  |  |
| **Progression-free survival events - N (%)** | 31 (96.9) | 35 (92.1) |  |  |
| **Progression-free survival (weeks) - n, median (IQR)** |  |  |  |  |
| **ITT population** | 32, 16.6 (7.1-21.7) | 38, 12 (5.6-18.7) | 0.83 (0.60-1.15) | 0.23 |
| **PP population** | 32, 16.6 (7.1-21.7) | 38, 12 (5.6-18.7) | 0.83 (0.60-1.15) | 0.23 |
| **Cox model adjusted\*** | 32, 16.6 (7.1-21.7) | 38, 12 (5.6-18.7) | 0.73 (0.52-1.02) | 0.11 |
| **Cox model adjusted\*\*** | 32, 16.6 (7.1-21.7) | 38, 12 (5.6-18.7) | 0.79 (0.54-1.17) | 0.22 |
| **Overall survival (weeks) - n, median (IQR)** |  |  |  |  |
| **ITT population** | 32, 59.4 (38.7-67.9) | 38, 31.3 (22.4-58.6) | 0.68 (0.37-1.26) | 0.22 |
| **Duration of follow up (weeks)\*\*\* - n, median (IQR)** | N/A | N/A |  |  |
|  |  |  |  |  |
| **\* Adjusted for stratification factors-smoking history and histology** | | | |  |
| **\*\* Adjusted for stratification factors, T-stage and N-stage** | | |  |  |
| **\*\*\* There were 3 patients that were still alive and not progressed at complete withdrawal and 1 patient that did not start study treatment in the ITT population. The median duration of follow up was not reached.** | | | | |
| **1 One-sided p-value for PFS. Two-sided p-value for OS.** | | |  |  |

Table 14: Patient withdrawal and death

|  |  |  |
| --- | --- | --- |
| **Table 14 : Patient withdrawal and death** | **Olaparib** | **Placebo** |
| N=32 | N=38 |
| **Withdrawal - N(%)** |  |  |
| Level 1 | 19 (59.4) | 20 (52.6) |
| Level 2 | 0 (0.0) | 0 (0.0) |
| Level 3 | 8 (25.0) | 10 (26.3) |
| Level 4 | 5 (15.6) | 8 (21.1) |
| Total | 32 (100.0) | 38 (100.0) |
| **Reasons for withdrawal from trial treatment - N(%)** |  |  |
| Clinical disease progression | 24 (75.0) | 33 (86.8) |
| Intolerance to treatment | 4 (12.5) | 1 (2.6) |
| Participant choice | 2 (6.3) | 1 (2.6) |
| Non-compliance | 0 (0.0) | 2 (5.3) |
| Incorrect enrolment | 1 (3.1) | 0 (0.0) |
| Maximum number of dose interruptions reached | 0 (0.0) | 1 (2.6) |
| Pneumonitis, fatigue | 1 (3.1) | 0 (0.0) |
| Total | 32 (100.0) | 38 (100.0) |
| **Death - N(%)** |  |  |
| Disease progression | 15 (46.9) | 20 (52.6) |
| Treatment related toxicity | 0 (0.0) | 0 (0.0) |
| Central chest pain | 0 (0.0) | 1 (2.6) |
| Not known | 3 (9.4) | 4 (10.5) |
| Total | 18 (56.3) | 25 (65.8) |

Table 15: EudraCT reportable non-serious adverse events

| **Table 15 : EudraCT reportable non-serious adverse events (>5% of patients experience the AE)** | **Subjects - N(%)** | | **Occurrences - N(%)** | |
| --- | --- | --- | --- | --- |
|  | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** |
|  | **N=31** | **N=38** | **N=31** | **N=38** |
| **Blood and lymphatic system** |  |  |  |  |
| Anaemia | 15 (48.4) | 10 (26.3) | 45 | 26 |
| Lymphopenia | 2 (6.5) | 2 (5.3) | 7 | 2 |
| Neutropenia | 4 (12.9) | 0 (0.0) | 6 | 0 |
| Thrombocytopenia | 4 (12.9) | 1 (2.6) | 12 | 3 |
| **Cardiac disorders** |  |  |  |  |
| Tachycardia | 2 (6.5) | 2 (5.3) | 2 | 3 |
| **Gastrointestinal disorders** |  |  |  |  |
| Constipation | 4 (12.9) | 4 (10.5) | 9 | 7 |
| Diarrhoea | 4 (12.9) | 7 (18.4) | 12 | 12 |
| Dry mouth | 1 (3.2) | 4 (10.5) | 1 | 5 |
| Dyspepsia | 3 (9.7) | 7 (18.4) | 4 | 13 |
| Flatulence | 1 (3.2) | 5 (13.2) | 1 | 3 |
| Nausea | 17 (54.8) | 11 (28.9) | 44 | 21 |
| Vomiting | 7 (22.6) | 4 (10.5) | 17 | 5 |
| **General disorders and administration site conditions** |  |  |  |  |
| Fatigue | 20 (64.5) | 25 (65.8) | 50 | 66 |
| Oedema peripheral | 3 (9.7) | 4 (10.5) | 8 | 6 |
| **Infections and infestations** |  |  |  |  |
| Upper respiratory infection | 4 (12.9) | 5 (13.2) | 7 | 9 |
| **Metabolism and nutrition disorders** |  |  |  |  |
| Anorexia | 11 (35.5) | 12 (31.6) | 22 | 21 |
| Hyponatremia | 3 (9.7) | 2 (5.3) | 3 | 3 |
| **Musculoskeletal and connective tissue disorders** |  |  |  |  |
| Arthralgia | 3 (9.7) | 2 (5.3) | 4 | 3 |
| Back pain | 5 (16.1) | 8 (21.1) | 6 | 10 |
| Dizziness | 6 (19.4) | 3 (7.9) | 6 | 3 |
| Headache | 6 (19.4) | 6 (15.8) | 8 | 6 |
| **Psychiatric disorders** |  |  |  |  |
| Insomnia | 2 (6.5) | 6 (15.8) | 9 | 8 |
| **Respiratory, thoracic and mediastinal disorders** |  |  |  |  |
| Coughing | 11 (35.5) | 22 (57.9) | 33 | 47 |
| Dyspnoea | 13 (41.9) | 15 (39.5) | 28 | 35 |
| **Skin and subcutaneous tissue disorders** |  |  |  |  |
| Alopecia | 3 (9.7) | 2 (5.3) | 3 | 1 |
| Rash | 4 (12.9) | 3 (7.9) | 10 | 3 |
| **Neoplasms benign, malignant and unspecified** |  |  |  |  |
| Pruritis | 3 (9.7) | 2 (5.3) | 10 | 2 |
| Hypertension | 3 (9.7) | 9 (23.7) | 15 | 18 |

Table 16: EudraCT reportable Serious Adverse Events

| **Table 16 : EudraCT reportable Serious Adverse Events** | **Subjects - N(%)** | | **Occurrences - N(%)** | | **Occurrences related to treatment - N(%)** | | **Deaths - N(%)** | | **Deaths related to treatment - N(%)** | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** | **Olaparib** | **Placebo** |
|  | **N=9** | **N=10** | **N=9** | **N=10** | **N=9** | **N=10** | **N=9** | **N=10** | **N=9** | **N=10** |
| **Cardiac disorders - N(%)** |  |  |  |  |  |  |  |  |  |  |
| Pericardial effusion | 0 (0.0) | 1 (10.0) | 0 (0.0) | 1 (10.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| **Gastrointestinal disorders - N(%)** |  |  |  |  |  |  |  |  |  |  |
| Diarrhoea | 0 (0.0) | 1 (10.0) | 0 (0.0) | 1 (10.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Nausea1 | 1 (11.1) | 0 (0.0) | 1 (11.1) | 0 (0.0) | 1 (11.1) | 0 (0.0) | 1 (11.1) | 0 (0.0) | 1 (11.1) | 0 (0.0) |
| Dysphagia | 1 (11.1) | 0 (0.0) | 1 (11.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (11.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Device occlusion | 0 (0.0) | 1 (10.0) | 0 (0.0) | 1 (10.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| **Infections and infestations - N(%)** |  |  |  |  |  |  |  |  |  |  |
| Lung infection | 0 (0.0) | 2 (20.0) | 0 (0.0) | 2 (20.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Skin infection | 1 (11.1) | 0 (0.0) | 1 (11.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| **Musculoskeletal and connective tissue disorders - N(%)** |  |  |  |  |  |  |  |  |  |  |
| Back pain | 1 (11.1) | 0 (0.0) | 1 (11.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| **Neoplasms benign, malignant and unspecified (incl cysts and polyps) - N(%)** |  |  |  |  |  |  |  |  |  |  |
| Pathological fracture imminent | 1 (11.1) | 0 (0.0) | 1 (11.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| **Nervous system disorders - N(%)** |  |  |  |  |  |  |  |  |  |  |
| Headache | 1 (11.1) | 1 (10.0) | 1 (11.1) | 1 (10.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Lethargy | 1 (11.1) | 0 (0.0) | 1 (11.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| **Psychiatric disorders - N(%)** |  |  |  |  |  |  |  |  |  |  |
| Suicide attempt | 0 (0.0) | 1 (10.0) | 0 (0.0) | 1 (10.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| **Respiratory, thoracic and mediastinal disorders - N(%)** |  |  |  |  |  |  |  |  |  |  |
| Dyspnea | 1 (11.1) | 2 (20.0) | 1 (11.1) | 2 (20.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Respiratory tract haemorrhage | 0 (0.0) | 1 (10.0) | 0 (0.0) | 1 (10.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |

1 Patient died WITH nausea that was related to treatment rather than DUE TO nausea